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MicroRNAs (miRNAs) have been one of the most contemplated topics in 
molecular biology studies in the last decade. These short, non-coding RNA 
molecules (21-25 nucleotides) were showed to play an important role in 
carcinogenesis with specific expression profiles in distinct cancer types. 
However, the contribution of deregulated miRNAs to medulloblastoma 
formation remains poorly understood. 
Medulloblastoma comprises the most frequent malignant brain tumor in 
childhood. Despite considerable therapeutic progress in the past decades, 
medulloblastoma still results in a comparably poor overall survival rate of 60-
70%. Among clinical variables, particularly metastatic dissemination at 
diagnosis, which is present in about 30% of cases, is associated with dismal 
prognosis.  
Distinct molecular subgroups with characteristic genomic aberrations and 
specific gene expression signatures were consistently reported by several 
groups and shown to be associated with largely different prognosis. 
This study demonstrates that genome-wide miRNA expression profiling 
largely reveals molecular subgroups that had previously also been identified by 
mRNA expression profiling. A robust miRNA signature with 26 miRNAs was 
found to readily distinguish Sonic hedgehog (SHH) subgroup medullo-
blastomas from other subgroups in two independent data sets obtained on 
different microarray platforms. 
Retina-specific miRNAs, miR-182, miR-183, and miR-96 were reported to be 
involved in the tumorigenesis and invasiveness of numerous cancer types, 
however, not yet studied in medulloblastoma. These miRNAs were the most 
differentially regulated miRNAs within the 26-miRNA signature, were 
significantly upregulated in non-SHH medulloblastoma, and were associated 
with tumor location and metastatic dissemination. Further investigating the 
functional role of these candidate miRNAs in medulloblastoma cells, this study 
clearly demonstrates in vitro and in vivo, that overexpression of miR-182 in the 
Summary	  	  
v	  
context of non-SHH medulloblastoma functionally contributes to the metastatic 
dissemination of medulloblastoma.  
This momentous finding regarding the functional role of retina-specific 
miRNAs in medulloblastoma proves novel insights in the biology of metastatic 
medulloblastoma. Based on this knowledge, novel targeted treatment 





In den letzten zehn Jahren sind MicroRNAs (miRNAs) einer der meist 
untersuchten Forschungsinhalte in molekularbiologischen Studien. Es wurde 
gezeigt, dass diese kleinen, nicht-kodierenden RNA-Moleküle (21-25 
Nukleotide) in der Tumorentstehung eine wichtige Rolle spielen. Auch wurde 
bereits nachgewiesen, dass verschiedene Krebsarten spezifische 
Expressionsprofile aufweisen. Allerdings ist der Beitrag der Deregulierung von 
miRNAs in Medulloblastomen noch weitgehend unverstanden. 
Das Medulloblastom ist der häufigste bösartige Hirntumor im Kindesalter. 
Trotz bedeutender therapeutischer Fortschritte in den vergangenen 
Jahrzehnten, ergibt sich für Medulloblastome eine vergleichsweise schlechte 
Überlebensrate von 60-70%. Bei jungen Patienten ist eine metastatische 
Ausbreitung von Tumorzellen zum Zeitpunkt der Diagnose, die derzeit in etwa 
30% der Fälle zu verzeichnen ist, mit einer schlechten Prognose verbunden. 
Aufgrund der großen Heterogenität dieser Tumorentität können 
verschiedene molekulare Subgruppen anhand der Ausprägung von 
genomischen Aberrationen und Genexpressionsprofilen unterschieden werden, 
welche sich auch bezüglich ihrer Prognose für die Patienten beträchtlich 
unterscheiden.  
Die vorliegende Arbeit ergab, dass genomweite miRNA-Expressionsprofile 
große Übereinstimmung mit den molekularen Subgruppen zeigten, die 
ihrerseits in früheren Studien auf der Basis von mRNA-Expressionsprofilen 
bestimmt worden waren. Darüber hinaus war es möglich, eine robuste miRNA-
Signatur mit 26 miRNA Kandidaten zu identifizieren, mit der Sonic hedgehog 
(SHH)-Medulloblastome von anderen Subgruppen unterschieden werden 
können.Dies konnte in zwei unabhängigen Kohorten auf unterschiedlichen 
Microarray-Plattformen nachgewiesen werden. 
Zusammenfassung	  	  
vii	  
Die Beteiligung der Retina-spezifischen miRNAs, miR-182, miR-183 sowie 
miR-96 an der Tumorentstehung und Invasivität von zahlreichen Krebsarten 
wurde bereits beschrieben. Eine Untersuchung bezüglich einer möglichen 
Beteiligung an der Entstehung von Medulloblastomen stand bisher allerdings 
aus. 
In nicht-SHH Medulloblastomen waren diese miRNAs signifikant 
hochreguliert und mit Tumorlokalisation und Metastasierung assoziiert, 
während sie in einer 26-miRNA Signatur die am meisten differentiell regulierten 
miRNAs darstellten. Diese miRNAs waren daher Gegenstand der vorliegenden 
Doktorarbeit. 
Weitere Untersuchungen zur funktionellen Rolle dieser miRNA-Kandidaten 
wurden in Medulloblastom-Zellen durchgeführt. Mittels in vitro und in vivo 
Analysen konnte gezeigt werden, dass die Überexpression von miR-182 in 
nicht-SHH Medulloblastomen zur metastatischen Ausbreitung von 
Medulloblastomen beiträgt. 
Diese Erkenntnisse über die funktionelle Rolle der Retina-assoziierten 
miRNAs in nicht-SHH Medulloblastomen liefern erste Hinweise auf eine 
mögliche Beteiligung dieser miRNAs an der Enstehung metastatischer 
Medulloblastome. Diese Erkenntnisse könnten einen Beitrag für die 
Entwicklung gezielter Therapiestrategien für Subgruppen mit besonders 




1	   INTRODUCTION	  
1.1	   The	  cerebellum	  
1.1.1	  Background	  
The cerebellum, comprises only 10% of human brain volume, but it contains 
more than half of all neurons in the human brain after maturation. Besides, it is 
the first brain structure undergoing differentiation, but the last part to complete 
maturation after birth. The cerebellum receives sensory input from the periphery 
to fine-tune body movements and balance, thus it is the coordination center of 
the human body (Wang et al. 2001). 
Anatomically, the cerebellum is located at the bottom of the skull (Fig.1-1), 
the biggest part of brain, the cerebrum, is right above it and a part of the 
midbrain called “pons” is in anterior of it. There is a solid layer called “tentorium 
cerebelli” between the cerebellum and the cerebrum to avoid overlaying. The 
only connection of the cerebellum to other parts of the brain is through the pons.  
 





Figure	   1-­‐2.	   Major	   anatomical	   divisions	   of	   the	   cerebellum.	   (Image	   from	  https://brassie.ece.jhu.edu/jamwiki/en/3D_Cerebellar_Anatomy)	  	  	  
The cerebellum can be divided into two hemispheres and a narrow midline 
zone, the vermis. There is a set of large folds to divide the overall structure into 
10 smaller "lobules" (Fig.1-2). The location of medulloblastoma is also indicated 
with these anatomic positions. Meanwhile, the fluid-filled cavity between the 
cerebellum and the pons is called the fourth ventricle. Together with three other 
connected cavities, the left and right lateral ventricles, and the third ventricle, 
they are known as the ventricular system. The fourth ventricle links the cerebral 
aqueduct and the central canal of the spinal cord, and is filled with cerebrospinal 
fluid (CSF) (Fig.1-3). When medulloblastoma invades into the forth ventricle, 





Figure	   1-­‐3.	   The	   ventricular	   system	   in	   human	   brain.	   (Image	   from	   (Bear	  2001))	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1.1.2	  Cerebellar	  development	  
During embryonic development, two different germinal zones serve as 
sources for the neurogenesis of different cell types in cerebellum. The dorso-
medial ventricular zone along the forth ventricle gives rise to Purkinje cells, 
which are the major output neurons of the cerebellar cortex, and also to other 
interneurons including Golgi, basket, and stellate cells. The second germinal 
zone for neurogenesis is comprised of cells within the rhombic lip called granule 
cell progenitors (GCPs). Several signaling pathways, such as the Sonic 
hedgehog (SHH) signaling pathway, promote the proliferation of GCPs and 
create an external granular layer (EGL) across the cerebellar anlage (Embryonic 
Day 12.5~15.5). After birth till the second postnatal week, GCPs exit the cell 
cycle and migrate inward to pass through the Purkinje cell layer and form a 
mature granular layer, the internal granule cell layer (IGL). Thus, the EGL 
entirely disappears within the first year after birth under physiologic conditions 
(Wang et al. 2001; Polkinghorn et al. 2007; Roussel et al. 2011). (Fig.1-4) 
 
 
Figure	  1-­‐4.	  Granule	  cell	  development.	  During	  the	  cerebellar	  development,	  GCPs	  receive	  SHH	  signals	  from	  Purkinje	  cells,	  which	  initiat	  proliferation	  of	  the	  EGL.	  After	  birth,	  GCPs	  exit	  the	  cell	  cycle	  and	  start	  to	  migrate	  through	  the	  PCL	  and	  form	  the	  IGL.	  (Image	  from	  (Polkinghorn	  et	  al.	  2007))	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1.2	   Medulloblastoma	  
1.2.1	  Clinical	  background	  
Medulloblastoma is classified as an embryonal brain tumor of the highest 
malignancy grade (grade IV) according to the WHO classification. It shares the 
specific embryonal cellular morphology with four other embryonal brain tumors, 
medulloepithelioma, ependymoblastoma, atypical teratoid/rhabdoid tumor, and 
supratentorial PNET (Louis et al. 2007).  
Typically medulloblastoma arise in the cerebellar midline and frequently 
invade the fourth ventricle. Invasion through the bottom part of the ventricle 
down to the brainstem is also observed (Polkinghorn et al. 2007) (Fig.1-5). 
Although advanced therapeutic strategies lead to a much better survival rate at 
around 60-70%, many surviving patients experience serious side effects, 
including cognitive impairment, psychiatric disorders, endocrine dysfunction, and 
skeletal growth retardation (Polkinghorn et al. 2007). 
 
Figure	   1-­‐5.	   MRI	   scan	   of	   a	   4-­‐year-­‐old	   child	   with	   medulloblastoma.	   The	  tumor	   mass,	   indicated	   by	   the	   green	   arrow,	   has	   invaded	   the	   fourth	  ventricle.	  (Image	  from	  (Polkinghorn	  et	  al.	  2007))	  
Introduction	  	  
6	  
The mean age of medulloblastoma diagnosis is between 3 and 7 years of age 
(Fogarty et al. 2005). Patient’s age at diagnosis has served one of the most 
important prognostic factors. Patients less than 3 years of age, who comprise 
around 25-35% of all medulloblastoma cases, overall have a much worse 
prognosis and are thus considered to be high-risk patients (Polkinghorn et al. 
2007). Patients older than 3 years are grouped into standard and high-risk 
groups according to metastatic stage. 
More than 30% of young medulloblastoma patients exhibit metastatic 
dissemination via the cerebrospinal fluid (CSF) (Fouladi et al. 1999). The 
presence of tumor cells in the CSF after surgery or macroscopic metastases 
along the cerebrospinal cord are considered signs of risk increment. Metastatic 
stage is classified according to Chang’s staging system into 5 stages from M0 
meaning no evidence of micrometastasis or macrometastasis to M4 meaning 
evidence of extraneural dissemination. The detailed descriptions are listed in 
table1A. 	  
Table1A.	  Chang’s	  metastasis	  staging	  system	  (Chang	  et	  al.	  1969)	  Metastasis	  stage	   Description	  M0	   No	   evidence	   of	   microscopic	   or	   macroscopic	  dissemination	  M1	   Microscopic	  tumor	  cell	  clusters	  	  found	  in	  the	  cerebrospinal	  fluid	  M2	   Macroscopic	  metastases	  demonstrated	  in	  the	  cerebellar,	  cerebral	   subarachnoid	   space	   or	   in	   the	   third	   or	   lateral	  ventricles	  by	  MRI	  M3	   Macroscopic	   metastases	   seedings	   in	   the	   spinal	  subarachnoid	  space	  M4	   Extraneuroaxial	  metastasis	  	  	   	  
Surgical removal of a tumor mass in the brain is different from removing 
tumors in other organs; neurosurgeons must keep the surrounding normal brain 
tissue untouched. Hence, the residual tumor size after surgery becomes another 
clinical variable to make risk assessment. In general, patients with tumor 
residues larger than 1.5 ml have an increased risk of tumor progression or 





Table1B.	  Prognostic	  risk	  assessment	  (Polkinghorn	  et	  al.	  2007)	  
Standard	  risk	   patients	  older	  than	  3	  years	  	  metastasic	  stage	  M0	  	  less	  than	  1.5	  ml	  of	  residual	  tumor	  postoperatively	  The	  5-­‐year	  survival	  rate	  for	  this	  group	  is	  67-­‐80%	  




Four histopathologic variances were described and summarized as classic, 
medulloblastoma with extensive nodularity (MBEN), desmoplastic, and large 
cell/anaplastic (LC/A) (Louis et al. 2007) (Fig.1-5). The classic subtype 
comprises about 60~68% of medulloblastoma is the most common one; it 
consists of small, dense, round and uniform cells. The MBEN subtype comprises 
the smallest portion of medulloblastoma with less than 5%, and mainly occurs in 
infants with good prognosis (Giangaspero et al. 1999). Around 25% of 
medulloblastomas are identified as desmoplastic subtype; these patients were 
reported to have a better prognosis than patients with classic, and LC/A subtype 
medulloblastoma (Jenkin et al. 2000). The LC/A subtype consists of mostly 
undifferentiated cells and comprises about 5% of medulloblastoma. They show a 
characteristic cell morphology with large, atypical nuclei and and are frequently 




Figure	   1-­‐5.	   Histopathologic	   types	   of	   medulloblastoma.	   (a)	   Classic	  medulloblastomas	  look	  like	  a	  sheet	  of	  small	  uniform	  cells	  with	  a	  compact,	  dense	   nucleus	   and	   a	   high	   nucleus-­‐to-­‐cytoplasm	   ratio.	   (b)	   Nodular/	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desmoplastic	  medulloblastomas	   show	  a	  mixed	  morphology	  with	  nodules	  of	   differentiated	   neuronal	   cells	   surrounded	   by	   low	   cell	   density	  desmoplastic	   internodular	   zones.	   (c)	   Anaplastic	   medulloblastomas	   are	  composed	   of	   pleomorphic	   cells	   with	   polyhedral	   forms	   and	   a	   high	   cell	  density.	  (d)	  Large-­‐cell	  medulloblastomas	  are	  comprised	  of	  groups	  of	  large	  uniform	   cells	   with	   vesicular	   nuclei	   and	   a	   single	   nucleolus.	   Anaplasia	   is	  especially	   observed	   within	   this	   medulloblastoma	   subtype.	   (Image	   from	  (Gilbertson	  et	  al.	  2008))	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1.2.3	  Cytogenetic	  aberrations	  in	  medulloblastoma	  
Cytogenetic aberrations have been established as important prognostic 
factors in medulloblastoma. Chromosome 17p deletion has been recognized as 
the most common chromosomal aberration in medulloblastoma for a long time. 
Many studies were focused on the impact of losing a copy of potential tumor 
suppresser genes on 17p and the prognostic role of 17p deletion in 
medulloblastoma (De Smaele et al. 2004). However, this chromosome alteration 
did not show a highly significant relationship with clinical outcome alone or 
further combined with isochromosome 17q[i(17q)], i.e. concomitant loss of 17p 
and gain of 17q (Cogen et al. 1992; Emadian et al. 1996; Biegel et al. 1997; 
Scheurlen et al. 1998; Gilbertson et al. 2001). Recent publication redefined the 
prognostic value of chromosome alteration on chromosome 17 in a large 
uniformly treated patient cohort (Pfister et al. 2009). It clearly showed gain of 
chromosome 17q or i(17q) to be associated with inferior prognosis. 
Medulloblastoma patients with chromosome 6q gain or a trisomy of 
chromosome 6, and amplification of MYC/MYCN have been shown to have the 
worst overall survival rates (Ellison 2002; Pfister et al. 2009). Furthermore, 
MYC/MYCN amplification is strongly associated with the LC/A subtype. In 
contrast, patients with medulloblastomas carrying a monosomy of 6 or have 
balanced copy-number profiles for 6q and 17q have a more favorable clinical 
outcome (Ellison 2002; Pfister et al. 2009).  
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1.2.4	  Molecular	  genetics	  of	  medulloblastoma	  
Medulloblastoma was first distinguished from other brain tumors in 1910 
(Wright 1910). However, after 100 years’ of research, the cellular origin of this 
tumor is still uncertain for some of the biological subgroups of medulloblastoma.  
A fraction of medulloblastomas arise from the granular cell progenitors (GCP) 
in the external granular layer of the cerebellum. Aberrant signaling pathways 
and proteins regulating normal GCP development and growth cause GCPs to 
insist proliferation or miss appropriate control signals for stopping GCP 
proliferation; this finally results in the formation of medulloblastoma (Marino 
2005; Knoepfler et al. 2006).  
Recent study showed the neuronal stem cells in the the ventricular zone (VZ) 
germinal matrix, another primary germinal epithelia of the cerebellum which 
gives rise to many neuronal and glial cell types in the cerebellum, also act as an 
origin of medulloblastoma via different aberrant signaling pathways (Fan et al. 
2008). 
Sutter R et al. demonstrated that both GCP and non-GCP like neuronal stem 
cells, or cerebellar stem cells, could give rise to medulloblastoma in mice 
recently. Moreover, different embryonal signaling pathways appear to be 
involved in the formation of tumors from different cells of origin (Sutter et al. 
2010). Altogether, these studies demonstrate that the origin of medulloblastoma 
is multiple. 
1.2.4.1	   Sonic	  hedgehog	  signaling	  pathway	  
The sonic hedgehog (SHH) signaling pathway is a key regulator of GCP 
proliferation. When SHH ligand binds to Patched 1 (PTCH1), it will release 
Smoothened (SMO). SMO in turn up-regulates downstream SHH targets, e.g., 
GLI family transpciption factors including GLI1, GLI 2, and GLI 3; meanwhile the 
GLI inhibitor suppressor-of-fused (SUFU) is getting inactivated. This result 
physiologically in an overall growth of the midbrain/hindbrain during embryonic 





Figure	  1-­‐6.	  Sonic	  hedgehog	  (SHH)	  signaling	  pathway.	  (A)	  In	  the	  absence	  of	   SHH	   ligand,	   SMO	   is	   suppressed	   by	   PTCH,	   thus	   the	   transcripton	   factor	  GLI	   is	   inhibited	  by	  SuFu	  and	  degreaded	   in	   the	  cytoplasm.	   (B)	  When	  SHH	  ligand	  is	  present,	  SMO	  gets	  released	  from	  PATCH	  inhibition	  and	  activates	  GLI.	  (C)	  In	  medulloblastom,	   loss	  of	  PATCH	  and	  mutation	  of	  SUFU	  or	  SMO	  cause	   aberrant	   activity	   of	   SMO.	   Increased	   GLI	   accumulation	   thus	  upregulates	  downstream	  targets	   that	  affect	  proliferation.	   (*	   indicates	   the	  aberrant	  protein	  in	  medulloblastoma)	  (Image	  from	  (Roussel	  et	  al.	  2011))	  	  	  
The first PTCH genetic modified mice model in the recent studies 
demonstrate that PTCH1 heterozygous knockout mice have a significantly lower 
incidence rate of medulloblastoma after inhibition of Gli1 suggesting that GLI 
has an important role in SHH-associated medulloblastoma formation (Kimura et 
al. 2005). In contrast to PTCH heterozygous mice with Tp53 knockout, PTCH1+/-
; Tp53-/-, showed faster medulloblastoma development and proliferation, also 
invasion into the brainstem matching the phenotype of SHH-driven tumors which 
have more serious metastatic dissemination in human (Gibson et al. 2010). 
SHH signaling also regulates the expression of many cell cycle regulators 
including cyclin D1 (CCND1) and cyclin D2 (CCND2) (Kenney et al. 2000). 
During early postnatal cerebellar development, GCPs express CCND1 in the 
beginning and both CCND1 and CCND2 are highly expressed during the peak 
of neuogenesis. Knocking out both Ccnd1 and PTCH1 in mice has been 
demonstrated to lead to an inhibition of medulloblastoma formation (Pogoriler et 
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al. 2006). Another major effect of constitutive SHH signaling is the upregulation 
of the proto-oncogene MYCN (Kenney et al. 2000). Upregulation of MYCN 
results in an activation of D-type cyclins and repress the expression of many 
cyclin-dependent kinase inhibitors, which might drive GCPs to stay in the cell 
cycle (Knoepfler et al. 2006).  
In medulloblastomas, about 25% exhibit SHH hyperactivation, frequently 
being associated with desmoplastic histology, and hemispheric tumor location 
(in contrast to the majority of medulloblastomas arising in the cerebellar midline) 
(Polkinghorn et al. 2007). 
 
1.2.4.2	   Wingless	  signaling	  pathway	  
Canonical Wingless (WNT) signaling pathway activation is initiated by the 
binding of Wnt ligand to its transmembrane receptor, Frizzled. This activates the 
Disheveled protein and destablizes a protein complex containing β-catenin 
(CTNNB1), GSK-3β, axin 1 and 2, the adenomatous polyposis coli (APC), and 
caseine kinase a (CK1a). Once CTNNB1 is released from the complex, it enters 
the nucleus and activates the transcription factors LEF/TCF1 thereby inducing 
the expression of downstream proliferative target genes such as MYC and 
CCND1. (Fig.1-7)  
Aberrant WNT signaling is observed in 10-15% of medulloblastomas. 
Deregulated WNT signaling is mainly caused by mutations in CTNNB1 
(Thompson et al. 2006), occasionally by mutations in APC and Axin (Gilbertson 
et al. 2008), and frequently associated with monosomy of chromosome 6. 
Monosomy 6 is the most recognizable prognostic factor in WNT subgroup 
medulloblastomas, and it is associated with favorable clinical outcome (Pfister et 
al. 2009). A study by Gibson et al. also demonstrated that normal stem cells 
derived from the lower rhombic lip carrying mutant CTNNB1 on a p53 negative 
background give rise to tumors with classic medulloblastoma histology in mice 





Figure	  1-­‐7.	  WNT	  signaling	  pathway.	  (A)	  In	  the	  absence	  of	  WNT	  ligand,	  the	  trans-­‐membrane	  receptor	  frizzled	  is	  inactivated	  and	  β-­‐catenin	  is	  kept	  in	  a	  complex	  with	   GSK-­‐3β	   kinase,	   axin	   1	   and	   2,	   CK1a,	   and	   APC;	   β-­‐catenin	   is	  getting	   degraded	   by	   the	   proteasome.	   (B)	   When	   WNT	   ligand	   is	   present,	  frizzled	  is	  activated	  leading	  to	  an	  inhibition	  of	  GSK-­‐3β	  kinase.	  β-­‐catenin	  is	  released	   from	   the	   complex	   and	   activates	   downsteam	   targets	   such	   as	   C-­‐Myc,	   and	   cyclinD1.	   (C)	   In	  medulloblastoma,	  mutated	   APC,	   CTNNB1,	   and	  hypermethylation	  of	  SFRP1	   leads	   to	   the	  accumulation	  of	  β-­‐catenin	   in	   the	  nucleus	  which	  leads	  to	  the	  constitutive	  activation	  of	  downstream	  targets.	  (Image	  from	  (Roussel	  et	  al.	  2011))	  
 
1.2.4.3	   Epigenetic	  mechanisms	  in	  medulloblastoma	  development	  	  
Epigenetic alterations also play a role in the development of medulloblastoma. 
Recent studies showed a lot of evidence for tumor-specific gene silencing by 
DNA methylation, such as silencing of the S100 gene family (Lindsey et al. 
2007), Kruppel-like factor 4 (Nakahara et al. 2010), and loss of WNT inhibition 
owing to the epigenetic silencing of SFRPs (Pfister et al. 2007). Conversely, 
secreted frizzled-related protein 1 (SFRP1) was found to be specifically 
overabundant in the SHH medulloblastoma subgroup, and may be used as a 
Introduction	  	  
15	  
specific immunohistochemistry marker to identify the SHH subgroup (Northcott 
et al. 2010). 
1.2.4.4	   Molecular	  subgrouping	  of	  medulloblastoma	  	  
Apart from developmental pathways as discussed above, many other 
signaling pathways and mechanisms are involved in medulloblastoma formation. 
Using high-throughput molecular genetic tools, several studies showed that 
medulloblastoma at least consists of four distinct molecular variants. WNT and 
SHH subgroups were consistantly separated by all studies, whereas the 
remaining tumors may be seprated into 2 to 4 groups (Kool et al. 2008; Cho et 
al. 2010; Northcott et al. 2010; Remke et al. 2011; Remke et al. in press). While 
cinical risk stratification algorithms were prone to misclassification rates of 20-
40% (Polkinghorn et al. 2007), taking molecular information into account will 
help to accurately assess the required treatment intensity for medulloblastoma 
patients in the near future. 
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1.3	   MicroRNAs	  
1.3.1	  Background	  
MicroRNAs (miRNAs) have been a major research focus in molecular biology 
for the last decade. They are endogenous, short (21-25 nucleotides), non-coding 
RNA molecules. Studies indicated that miRNAs control many cellular activities 
via regulation of almost 60% of protein-coding genes (Fabian et al. 2010). 
Furthermore, they also playing important roles in almost every cellular process 
and in tumorigenesis. Moreover, they have specific expression profiles in 
different somatic tissues and cancer types (He et al. 2005; Lu et al. 2005; 
Bushati et al. 2007). 
However, the specific roles of miRNAs in medulloblastoma are rarely 
concerned. The only consistent finding to date was the identification of the miR-
17/92 cluster as an oncogene in SHH-driven medulloblastoma (Northcott et al. 
2009; Uziel et al. 2009). 
Based on bioinformatic predictions, it is now believed that miRNAs control the 
activity of more than 60% of the mammalian protein coding genes (Friedman et 
al. 2009), however the detailed mechanism underlying the role of miRNAs as 
protein synthesis regulator is still unclear. From the current knowledge, most 
miRNAs regulate gene expression post-transcriptionally through binding to the 
3`-untranslated region (3`-UTR) of their target mRNA via base-pairing, either by 
perfect match functionally as small interfering RNAs (siRNAs) which leads to the 
degrdation of target mRNA, or via partial complementary sequences leading to 




1.3.2	  The	  biogenesis	  of	  microRNAs	  
The initiation of miRNA biogenesis takes place inside the nucleus. Primary 
miRNAs (pri-miRNAs) are either transcribed from independent miRNA genes or 
from the intron region of protein coding genes by using RNA polymerase II. A 
single pri-miRNA might be up to 1Kb or longer in size and includes 5`-caps and 
3`ploy(A) tails. The pri-miRNA transcript folds into a hairpin structure with 
imperfect hairpin loops containing signals for dsRNA-specific nuclease 
cleavage. Besides, one pri-miRNA might carry one or multiple miRNAs. Such 
miRNAs that are located closely together within around 1Kb distance are 
frequently called a miRNA cluster. 
The second step of miRNA processing is the cleavage of the pri-miRNA into a 
precursor miRNA (pre-miRNA). This step is catalyzed by the dsRNA-specific 
ribonuclease III (RNaseIII) endonuclease, Drosha, and its partner dsRNA 
binding protein, DiGeorge syndrome critical region gene 8 (DGCR8). The 
Drosha-DGCR8 complex cleaves the long pri-miRNA into a ~70-nucleotide 
hairpin-shaped pre-miRNA. The pre-miRNA is directly exported from the nucleus 
to the cytoplasm by Exportin-5, which is thereby essential for miRNA biogenesis 
(Yi et al. 2003; Bohnsack et al. 2004). 
Once the pre-miRNA enters the cytoplasm, another complex including 
RNAaseIII endonuclease, Dicer, and the dsRNA binding protein, TAR RNA 
binding protein (TRBP), cleaves the pre-miRNA into a ~21-nucleotide mature 
miRNA duplex. One strand, usually the 5` end, is released to function as mature 
miRNA, whereas the other stand is degraded (Du et al. 2005; Bushati et al. 
2007; Peters et al. 2007; Filipowicz et al. 2008). 
Mature miRNAs are then incorporated into a ribonucleoprotein (RNP) 
complex called micro-RNPs (miRNPs) or miRNA-induced silencing complex 
(miRISC). These complexes are getting established by proteins of the 
Argonaute (AGO) family. AGO proteins including AGO1 to AGO4 collaborate 
with mature miRNAs to regulate protein synthesis via imperfect base-pair 
binding at the 3`-UTR of target mRNAs, whereas only AGO2 works in concert 
with siRNAs in the 3`-UTR of target mRNA to inhibit translation via cleavage of 









1.3.3	  Mechanisms	  of	  miRNA	  deregulation	  in	  human	  cancer	  
It is well established, that micro-RNAs may act as either tumor suppressors or 
oncogenes during tumorigenesis (Deng et al. 2008; Medina et al. 2008). The 
basic biological function of miRNAs is the reduction of protein levels of target 
genes. However, recent studies also showed that some miRNAs are capable of 
activating mRNA translation (Vasudevan et al. 2007; Orom et al. 2008). Several 
studies in different cancer entities have provided evidence that miRNA 
dysfunction in human cancer is caused by multiple underlying mechanisms.  
 
1.3.3.1	   Transcriptional	  deregulation	  of	  miRNAs	  
The oncogene c-MYC, a frequently reported deregulated gene in human 
cancer, works closely together with the miR-17/92cluster, and the expression of 
many other miRNAs are also regulated by the transcription factor c-Myc 
(O'Donnell et al. 2005; Chang et al. 2008). When c-Myc is aberrantly 
upregulated in human cancer, it also upregulates the expression of the miR-
17/92 cluster to cooperatively accelerate tumor cell proliferation and confer 
resistance to apoptosis (He et al. 2005). Thus, the miR-17/92 cluster is a 
prototypic cluster of “onco-miRs”. 
Conversely, the tumor suppressor gene TP53 activates the transcription of 
the tumor suppressor miRNA miR-34 family; they cooperate in control of cell 
proliferation (Corney et al. 2007; Hermeking 2007). Thus, transcriptional 




1.3.3.2	   Epigenetic	  regulation	  of	  miRNA	  genes	  
Epigenetic alterations including DNA methylation and histone modification 
have important roles in the regulation of protein-coding gene expression and 
chromatin remodeling in human cancer (Esteller 2008). DNA hypermethylation 
in the miRNA 5′-UTR is an important mechanism for the down-regulation of 
miRNA expression in many tumor types (Saito et al. 2006; Lujambio et al. 2007). 
Recent evidence indicates that epigenetic silencing accounts for 36% of 
miRNA down-regulation in epithelial ovarian cancer (Zhang et al. 2008). 
Whereas hypermethylation of the miR-124a promoter region also causes the 
silencing of miR-124a expression and activation of the cyclin D–kinase 6 
(CDK6), a bona fide oncogene (Lujambio et al. 2007). 
 
1.3.3.3	   Germline/somatic	  mutation	  of	  miRNAs	  
Germline or somatic mutations of protein-coding genes leading to the loss- or 
gain-of-function of tumor suppressor genes or oncogenes are widely reported in 
human cancer. The frequent deletion of the chromosome region13q14 in chronic 
lymphocytic leukemia (CLL) was the first direct evidence that miRNAs play a 
role in human cancer (Dohner et al. 2000). Sutdies focusing on the identification 
of germline mutation in CLL found A/C to T mutations in the pri-miRNA of miR-
16-1 and miR-15a in 2 out of 75 patients. The authors demonstrated that miR-
15a and miR-16-1, which are located at 13q14 were deleted in more than 50% 
of CLL patients, and consecutively showed reduced expression of these 
miRNAs (Bullrich et al. 2001; Calin et al. 2002).  
Another more recent study also demonstrated DNA copy- number losses to 
cause downregulation of miRNA expression in approximately 15% of epithelial 
ovarian cancer (Zhang et al. 2008). Furthermore, these mutations are 
associated with lower expression of the mature miRNAs (Calin et al. 2004). 
Another study also identified single nucleotide polymorphisms (SNPs) 
distributed in the region of pri-, pre-, and mature miRNAs in human tumor 
tissues and cancer cell lines. However, most of these mutations did not reduce 
the expression of miRNAs, only one mutation found in miRNA let-7e caused a 
significant reduction of expression in vivo (Wu et al. 2008).  
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1.4	   MicroRNA	  profiling	  in	  medulloblastoma	  
Modern high-throughput miRNA quantification technologies helped scientists 
to evaluate miRNA expression profiles in human cancer in a more reliable and 
faster way. Genome-wide miRNA expression studies revealed close 
associations between miRNA clusters and tumor subtype as well as clinical 
subgroups (Zhang et al. 2008; Ferretti et al. 2009). 
In medulloblastoma, first miRNA profiling studies demonstrated that it is 
possible by miRNA signatures to discriminate histological subtype, e.g., classic 
from anaplastic medulloblastomas. Furthermore, miR-31 and miR-153 were 
shown to be downregulated in clinical high risk patients (Ferretti et al. 2009; 
Pang et al. 2009). Another study identified the miR-17/92 cluster to be 
significantly upregulated in SHH-driven medulloblastoma. The authors confirmed 
that these miRNAs promote proliferation and contribute to the development of 
medulloblastoma in vitro and in vivo (Northcott et al. 2009; Uziel et al. 2009). 
In the present study as well as in a recent report by Cho et al. (Cho et al. 
2010), the miR-183~96~182 cluster was found to be significantly associated with 
non-SHH medulloblastoma.  
The miR-183~96~182 cluster was first reported to be highly expressed in 
adult murine retina (Xu et al. 2007). The authors confirmed the specific high 
expression levels of these miRNAs in retinal photoreceptors and the 
interneurons in the inner nuclear layer, but did not detect any expression in adult 
brain or other tissues. The cluster consists of three members, namely miR-182, 
miR-183, and miR-96, which are located closely together on mouse 
chromosome 6qA3 and the orthologous human chromosome 7q32.2, 
respectively. Moreover, both miRNA sequences in mouse and human are 
identical indicating that they are highly conserved between species. The genes 
within 4kb of these miRNAs are transcribed in the same direction (telomere to 
centromere) and have a large upstream CpG island together with multiple 
transcription factor binding sites, such as for OTX1 (Xu et al. 2007).  
Recent studies reported these miRNAs to be deregulated in diverse types of 
human cancer including melanoma, medulloblastoma, breast cancer, pancreatic 
cancer, and lung cancer. However the reported mechanism of aberrant 
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expression, and functional impact of overabundance seems to be cell-type 
specific since they were largely different between different entities (Segura et al. 
2009; Cho et al. 2010; Gokhale et al. 2010; Lowery et al. 2010; Yu et al. 2010; 
Zhang et al. 2011). 
During this dissertation work, Cho et al. reported the distinct miRNA 
expression profiles in medulloblastoma subgroups (Cho et al. 2010). 
Coincidently, they also find the miR-183~96~182 is associated with non-SHH 
subgroups with another patient cohort in the US. However, the here presented 
provided more information about the detail functional role of the miR-183 family 
in medulloblastoma. 
In summary, the miR-183~96~182 cluster might have different, even 
opposing functions in different cellular contexts. Thus, it was intriguing to unravel 




1.5	   Technical	  introduction	  –	  The	  3D	  microchannel	  
migration	  assay	  
The most commonly used in vitro functional assays to assess cell migration 
or invasion have been carried out on a flat surface (i.e. in two dimensions). 
Examples for such assays include the scratch assay (also called wound-healing 
assay), for which cells are seeded on plastic culture dishes or chambered glass 
slides, or the Boyden chamber assay, which is carried out on a polyethylene 
terephthalate (PET) or polycarbonate membrane with small pores on it (Fig.1-9). 	  
	  
Figure	  1-­‐9.	  Cell	  migration	  directions	  in	  commonly	  used	  two	  dimensional	  
in	  vitro	  migration	  assays.	  Migration	  of	   seeded	  cells	   in	   the	  wound-­‐healing	  assay	  is	  observed	  on	  a	  plain	  surface,	  and	  directed	  towards	  the	  cells	  at	  the	  opposite	   side	  of	   the	  wound.	   In	   the	  Boyden	  chamber	  assay,	   the	   cells	  may	  vertically	   pass	   through	   the	   pores	   of	   the	   membrane	   from	   the	   upper	  chamber	  to	  the	  lower	  chamber.	  To	  assess	  invasion,	  the	  membrane	  may	  be	  coated	  with	  extracellular	  matrix	  proteins,	  e.g.	   the	  matrigel,	   in	  a	  way	   that	  the	   cells	   have	   to	   pass	   through	   this	   layer	   first	   before	   they	   can	   pass	  throuogh	  the	  pores	  of	  the	  membrane.	  	   	  	  
The main limitation of these two dimensional (2D) environments might be, 
that they do not correctly represent the situation in vivo (Fig.1-10). Former 
studies have shown that the malignant phenotype of breast cancer cells can be 
reversed to a non-malignant phenotype by applying beta1-integrin antibody 
treatment in a three dimensional (3D) culture system and in vivo, which could 




Figure	   1-­‐10.	   Different	   cell	   morphologies	   and	   behaviors	   in	   2D	   and	   3D	  culture.	  (Image	  from	  (Weaver	  et	  al.	  1997))	  	  	  
To provide a better in vitro model to reproduce the in vivo 3D environment 
adequately, our collaborators, Dr. Ralf Kemkemer and Claudio Rolli from the 
Max Planck Institute for Intelligent Systems, Stuttgart, Germany, have created a 
micro-fabricated device with channel structures mimicking an in vivo 3D 




Figure	   1-­‐11.	   Schematic	   view	   of	   a	   3D	   microchannel	   structure.	   (Image	  from(Rolli	  2008)	  )	  	  	  
The microchannel structure is made from Poly(dimethylsiloxane) (PDMS), 
which is a non-toxic, biologically inert, optically transparent, easy to handle and 
commercially available material. PDMS is very hydrophobic but its surface is 
treated with a thin oxidized layer, which facilitated secure mounting onto a glass 
surface (Rolli 2008). The schematic view in Fig. 1-11 and the microscopic view 
in Fig. 1-12 illustrate the two reservoirs, which are separated by the channel 
structures through which the cells migrate. An inverted microscope underneath 
Reservoir Reservoir Channel 
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enables to observe cell migration through the microchannels in real-time. The 
difference between the experimental set up in this study and the original design 
(Rolli 2008) is that the two reservoirs in our setup contain the same culture 
medium and thus cells pass through the channel spontaneously without any 
chemoattraction. 	  
	  




1.6	   Aim	  of	  the	  study	  
This study aimed to identify miRNA-based pathomechanisms, subgroup-
specific microRNA signatures (including prognostic markers), and the functional 
impact of their respective target genes in medulloblastoma.  
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2	   MATERIALS	  AND	  METHODS	  
2.1	   Materials	  
2.1.1	  Biochemical	  reagents	  
Substance Supplier 
2-mercaptoethanol  Sigma Aldrich, Munich, Germany  
40% Acrylamide/Bis Solution (1:29) BioRad, Munich, Germany 
Agarose  Sigma Aldrich, Munich, Germany  
Ammoniumpersulfate (APS) Roth, Karlsruhe, Germany  
Ampicillin  Roche Diagnostics, Mannheim, Germany  
Bacto Agar  Difco Laboratories, Detroit, USA  
Bacto tryptone  Difco Laboratories, Detroit, USA  
Bacto yeast extract  Difco Laboratories, Detroit, USA  
Bromophenole blue  AppliChem, Darmstadt, Germany  
Copper-(III)-sulfate  Sigma Aldrich, Munich, Germany  
Dimethylsulfoxide  Sigma Aldrich, Munich, Germany  
Dithiothreitol  Sigma Aldrich, Munich, Germany  
Ethanol  Merck, Darmstadt, Germany  
Ethidium bromide  Sigma Aldrich, Munich, Germany  
Glycerol  Roth, Karlsruhe, Germany 
Glycine  Roth, Karlsruhe, Germany  
Hydrochloric acid  Merck, Darmstadt, Germany  
Magnesium chloride  Merck, Darmstadt, Germany  
Methanol  Merck, Darmstadt, Germany  
Nuclease free water  Ambion, Austin, USA  
Rnase free water Qiagen, Hilden, Germany  
Skim milk powder (blotting grade) Sigma Aldrich, Munich, Germany  
SOC medium  Invitrogen, Karlsruhe, Germany  
Sodium chloride  Merck, Darmstadt, Germany  
Sodium acetate  Merck, Darmstadt, Germany  
Sodium dodecyl sulfate  Sigma Aldrich, Munich, Germany  
Tetramethylethylenediamine 
(TEMED) Roth, Karlsruhe, Germany  
Tris-base  Sigma Aldrich, Munich, Germany  
Tween 20 Sigma Aldrich, Munich, Germany  
Zeocin Invitrogen, Karlsruhe, Germany  	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2.1.2	  Solutions	  and	  Buffers	  
Solution Composition 
Laemmli-buffer (5x)  
8 % SDS, 200 mM Tris, 0.08 % 
bromphenol blue, 40 % glycerol, 10 % 2-
mercaptoethanol, pH 6.8  
Phosphate buffered saline 
(PBS)  
137 mM NaCl, 2.7 mM KCl, 9.2 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.4  
SDS-PAGE buffer  25 mM Tris, 200 mM glycine, 0.5% SDS, pH 8.8  
Western Blot stripping solution  62.5 nM Tris-HCl, 2% SDS, 200 nm 2-mercaptoethanol, pH 6.7  
Tris-borate-EDTA (TBE)  89 mM boric acid, 89 mM Tris-base, 2 mM EDTA,pH 8.0  
Tris buffered saline (TBS)  150 mM NaCl, 10 mM Tris, pH 7.4  
Tris buffered saline Tween20  
(TBS-T)  
150 mM NaCl, 10 mM Tris, 0.05% (v/v) 
Tween20, pH 7.4  	  
2.1.3	  Enzymes	  
Enzyme name Supplier 
BamH1 Roche Diagnostics, Mannheim, Germany  
EcoR1 Roche Diagnostics, Mannheim, Germany  
FastStart Taq DNA Polymerase Roche Diagnostics, Mannheim, Germany  
MultiScribe Reverse 
Transcriptase Applied Biosystems, Foster City, USA  
Proteinase K Roche Diagnostics, Mannheim, Germany  
Rnase A Qiagen, Hilden, Germany  
T4 Ligase  Fermentas, St. Leon-Roth, German 
Xho1 Roche Diagnostics, Mannheim, Germany  
DNase  Roche Diagnostics, Mannheim, Germany  	  
2.1.4	  Medulloblastoma	  cell	  lines	  
Name Provider / Supplier 
D458Med Dr. Darell D. Bigner, Duke University North Carolina, USA 
DAOY (Cat#HTB-186) American Type Culture Collection (ATCC), Manassas, USA 
Med8A Dr. Michael D. Taylor, University of Toronto, Canada 	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2.1.5	  Cell	  culture	  
Reagent Supplier 
24-well / 6well culture plate SPL Life Sciences, Gyeonggi-do, Korea 
6.5mm Transwell with 8um Pore 
Polycarbonate Membrane insert 
Corning Sigma Aldrich, Munich, 
Germany 
BD BioCoat 24-well Matrigel 
invasion chambers BD Biosciences, Heidelberg, Germany 
Dulbecco´s Modified Eagle Medium 
(DMEM) Sigma Aldrich, Munich, Germany 
Fetal bovine serum (FBS) Gibco Invitrogen, Karlsruhe, Germany  
Filtered screw cap culture flask TPP Techno Plastic Products, Trasadingen, Switzerland 
Improved MEM Zn++ Option 
(Richter’s Modification) Gibco Invitrogen, Karlsruhe, Germany  
Lab-Tek II Chambered Coverglass 
(8-well) 
Nunc Thermo Scientific, 
Langenselbold, Germany 
Opti-MEM I Reduced-Serum 
Medium Gibco Invitrogen, Karlsruhe, Germany  
Penicillin/Streptomycin (1000 U/ml)  Gibco Invitrogen, Karlsruhe, Germany  
Phosphate Buffered Saline (PBS) Gibco Invitrogen, Karlsruhe, Germany  
Trypsin/EDTA (0.05%w/v)  Invitrogen, Karlsruhe, Germany 	  	  
2.1.6	  Kits	  
Product name Supplier 
AllPrep RNA/Protein Kit Qiagen, Hilden, Germany 
BigDye Terminator Sequencing kit  Applied Biosystems, Foster City, USA  
ECL Western Blot detection kit  GE Healthcare, Munich, Germany  
FastStart High Fidelity PCR System Roche Diagnostics, Mannheim, Germany  
miRNeasy Mini Kit Qiagen, Hilden, Germany  
QIAamp DNA Mini Kit Qiagen, Hilden, Germany  
QIAGEN Plasmid Maxi Kit Qiagen, Hilden, Germany  
QIAprep Spin Miniprep Kit Qiagen, Hilden, Germany  
QiaQuick gel extraction kit  Qiagen, Hilden, Germany  
QIAquick PCR Purification Kit Qiagen, Hilden, Germany  
RNA 6000 Nano kit  Agilent Technologies, Santa Clara, USA 
TaqMan MicroRNA Reverse 
Transcription Kit Applied Biosystems, Foster City, USA  
TaqMan Universal PCR Master Mix Applied Biosystems, Foster City, USA  
TOPO TA Cloning Kits Invitrogen, Karlsruhe, Germany 	  




2.1.7	  Taqman	  probes	  and	  anti-­‐miR	  siRNA	  
Product name & ID Supplier 
TaqMan MicroRNA Assays 00597, 
has-miR-182 Applied Biosystems, Foster City, USA  
TaqMan MicroRNA Assays 000484, 
has-miR-183 Applied Biosystems, Foster City, USA  
TaqMan MicroRNA Assays 000434, 
has-miR-96 Applied Biosystems, Foster City, USA  
TaqMan MicroRNA Assays 001093, 
RNU6B Applied Biosystems, Foster City, USA  
TaqMan MicroRNA Assays 001002, 
RNU66 Applied Biosystems, Foster City, USA  
TaqMan Gene Expression Assay, 
HMGA2 Applied Biosystems, Foster City, USA  
Ambion Anti-miR miRNA Inhibitor, 
AM12369, hsa-miR-182 
Ambion, Applied Biosystems, Foster 
City, USA  
Ambion Anti-miR miRNA Inhibitor, 
AM12830, hsa-miR-183 
Ambion, Applied Biosystems, Foster 
City, USA  
Ambion Anti-miR miRNA Inhibitor, 
AM10422, hsa-miR-96 
Ambion, Applied Biosystems, Foster 
City, USA  
Ambion Anti-miR miRNA Inhibitor, 
AM17010, Negative Control #1 
Ambion, Applied Biosystems, Foster 
City, USA  
Anti-miR hsa-let-7c miRNA Inhibitor 
Positive Control 
Ambion, Applied Biosystems, Foster 
City, USA  	   	  
2.1.8	  Softwares	  
Software name & version Supplier 
Adobe Photoshop CS2  Adobe, Dublin, Rep. of Ireland  
AxioVision 4.7 Carl Zeiss, Jena, Germany 
AxioVision LE Release 4.8.2. Carl Zeiss, Jena, Germany 
BeadStudio ver.3 Illumina, San Diego, USA 
ImageJ Version 1.44 http://rsbweb.nih.gov/ij/index.html 
MultiExperiment Viewer (TM4) 4.3 http://www.tm4.org/mev/ 
R 2.2.2  http://www.r-project.org/  
SDS 2.0  Applied Biosystems, Foster City, USA 
Sequence Scanner Software v1.0  Applied Biosystems, Foster City, USA 
SigmaPlot 10.0 Systat Software, San Jose, USA 	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2.1.9	  Instruments	  
Instrument model Supplier 
2100 Bioanalyzer Agilent Technologies, Santa Clara, USA 
3130 Genetic Analyzer Applied Biosystems, Foster City, USA  
96-Well GeneAmp PCR System 
9700 Applied Biosystems, Foster City, USA  
ABI PRISM 7900 Sequence 
Detection System  Applied Biosystems, Foster City, USA  
Axioskop 40 microscope  Carl Zeiss, Jena, Germany  
Axiovert 200M Cell Observer Carl Zeiss, Jena, Germany 
BeadArray Reader Illumina, San Diego, USA 
Gel electrophoresis power supply  E-C Apparatus Corporation, Holbrook, USA  
Heating block QBT  Grant Instruments, Cambridge, UK  
Mikro-Disemebrator S B.Braun Biotech International, Melsungen, Germany 
Mini Protean gel electrophoresis 
system BioRad, Munich, Germany  
Mini Trans-Blotwet gel transfer 
system BioRad, Munich, Germany  
NanoDrop ND-1000 spectrometer  NanoDrop, Wilmington, USA  
Symphony whole-body 1.5 T MRI 
scanner  Siemens, Erlangen, Germany  
Universal Microplate Reader Bio-Tek Instruments, Winooski, USA 
UV Gel Documentation  BioRad, Hercules, USA  
Varifuge 3.0  Heraeus Instruments, Hanau, Germany  
Vi-CELL XR 2.03  Beckman Coulter, Krefeld, Germany  	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2.1.10	   Miscellaneous	  
Product name Supplier 
Anti-β-actin antibody  
(mouse monoclonal anti-human) 
Santa Cruz Biotechnology, Santa Cruz, 
USA 
Anti-SFRP1 antibody  
(Rabbit polyclonal anti-human) Abcam, Cambridge, UK 
BLOCK-iT Alexa Fluor Red 
Fluorescent Control Invitrogen, Karlsruhe, Germany 
CellTiter 96 AQueous Non-
Radioactive Cell Proliferation Assay 
(MTS) 
Progema,Madison, USA 
DNA ladders (100 bp, 1 kb) Fermentas, St. Leon-Roth, German 
Goat anti-mouse secondary 
antibody, HRP-coupled Cell Signaling, Danvers, USA  
Goat anti-rabbit secondary antibody, 
HRP-coupled Cell Signaling, Danvers, USA  
Lipofectamine 2000 Invitrogen, Karlsruhe, Germany 
One Shot TOP10 Chemically 
Competent E. coli Invitrogen, Karlsruhe, Germany 
Polyvinyliden flouride (PVDF) 
membrane 
Roche Diagnostics, Mannheim, 
Germany  
Strips of 8 Thermo-Tubes & flat cap 
strips 
Thermo Fisher Scientific, Waltham, 
USA 
Spectra multicolor broad range 
ladder Fermentas, St. Leon-Roth, German 
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2.2	   Methods	  
2.2.1	  Clinical	  materials	  	  
All medulloblastoma tissue samples were contoinuously collected by Dr. 
Andrey Korshunov at the Department of Neuropathology, Burdenko Institute, 
Moscow, Russia, between 1994 and 2007 (n=111) after informed consent to all 
patients. Diagnoses were confirmed by histological and immunohistochemical 
assessment following the criteria of the WHO classification by at least two 
neuropathologists including a central pathology review in Moscow (Louis et al. 
2007). Approval to link laboratory data to clinical and pathological data was 
obtained from the institutional review board. Metastatic disease was detected by 
cranio-spinal imaging and cerebrospinal fluid cytology following the Chang 
classification (Chang et al. 1969). All patients were treated according to 
standardized therapy protocols of the German HIT study group (Kortmann et al. 
2000; von Hoff et al. 2009). 
	  
Table	  2A	  Clinical-­‐pathological	  characteristics	  of	  the	  patients	  
Screening	  data	  set	  
	   Medulloblastoma	  Subtypes	   Fisher’s	  
exact	  test	  Variable	   SHH	   WNT	   Group	  C	   Group	  D	   All	  11	   (34.4%)	   4	   (12.5%)	   3	   (9.4%)	   14	   (43.8%)	   32	   (100%)	   P	  
Age,	  years	   	   	   	  	   	   	   	   	   	   	   	  ≤3	   3	   (27.3%)	   0	   (0.0%)	   	  1	   (33.3%)	   0	   (0.0%)	   4	   (12.5%)	   	  4-­‐17	   4	   (36.4%)	   3	   (75.0%)	   2	   (66.7%)	   10	   (71.4%)	   19	   (53.1%)	   0.03	  ≥18	   4	   (36.4%)	   1	   (25.0%)	   0	   (0.0%)	   4	   (28.6%)	   9	   (34.4%)	   	  
Gender	   	   	   	   	   	   	   	   	   	   	   	  Female	   1	   (9.1%)	   2	   (50.0%)	   1	   (33.3%)	   5	   (35.7%)	   9	   (28.1%)	   0.25	  Male	   10	   (90.9%)	   2	   (50.0%)	   2	   (66.7%)	   9	   (64.3%)	   23	   (71.9%)	  
Localisation	   	   	   	   	   	   	   	   	   	   	   	  Hemispheric	   8	   (72.7%)	   1	   (25.0%)	   0	   (0.0%)	   1	   (7.1%)	   10	   (31.2%)	   <0.01	  Midline	   3	   (27.3%)	   3	   (75.0%)	   3	   (100.0%)	   13	   (92.9%)	   22	   (68.8%)	  
Histology	   	   	   	   	   	   	   	   	   	   	   	  Classic	   4	   (36.4%)	   4	   (100.0%)	   0	   (0.0%)	   11	   (78.6%)	   19	   (59.4%)	   	  MBEN/	  desmoplastic	   5	   (45.5%)	   0	   (0.0%)	   0	   (0.0%)	   0	   (0.0%)	   5	   (15.6%)	   <0.01	  L/CA	   2	   (18.2%)	   0	   (0.0%)	   3	   (100.0%)	   3	   (21.4%)	   8	   (25.0%)	   	  
Metastatic	  stage	   	   	   	   	   	   	   	   	   	  M0	   7	   (63.6%)	   3	   (75.0%)	   2	   (66.7%)	   6	   (42.9%)	   18	   (56.2%)	   0.66	  M1-­‐3	   4	   (36.4%)	   1	   (25.0%)	   1	   (33.3%)	   8	   (57.1%)	   14	   (43.8%)	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Table	  2A	  (cont’d.)	  
QRT-­‐PCR	  validation	  data	  set	  
	   Medulloblastoma	  Subtypes	   Fisher’s	  
exact	  test	  Variable	   SHH	   WNT	   Group	  C	   Group	  D	   All	  30	   (38.0%)	   7	   (8.9%)	   14	   (17.7%)	   28	   (35.4%)	   79	   (100.0%)	   P	  
Age,	  years	   	   	   	   	   	   	   	   	   	   	   	  ≤3	   8	   (26.7%)	   0	   (0.0%)	   2	   (14.3%)	   0	   (0.0%)	   10	   (12.7%)	   	  4-­‐17	   15	   (50.0%)	   4	   (57.1%)	   11	   (78.6%)	   23	   (82.1%)	   55	   (69.6%)	   0.01	  ≥18	   7	   (23.3%)	   3	   (42.9%)	   1	   (7.1%)	   5	   (17.9%)	   14	   (17.7%)	   	  
Gender	   	   	   	   	   	   	   	   	   	   	   	  Female	   11	   (36.7%)	   3	   (42.9%)	   4	   (28.6%)	   9	   (32.1%)	   27	   (44.2%)	   0.91	  Male	   19	   (63.3%)	   4	   (57.1%)	   10	   (71.4%)	   19	   (67.9%)	   52	   (65.8%)	  
Localisation	   	   	   	   	   	   	   	   	   	   	   	  Hemispheric	   8	   (26.7%)	   2	   (28.6%)	   0	   (0.0%)	   1	   (3.6%)	   11	   (13.9%)	   0.01	  Midline	   22	   (73.3%)	   5	   (71.4%)	   14	   (100.0%)	   27	   (96.4%)	   68	   (86.1%)	  
Histology	   	   	   	   	   	   	   	   	   	   	   	  Classic	   24	   (80.0%)	   7	   (100.0%)	   12	   (85.7%)	   28	   (100.0%)	   71	   (89.9%)	   0.10	  MBEN/	  desmoplastic	   5	   (16.7%)	   0	   (0.0%)	   1	   (7.1%)	   0	   (0.0%)	   6	   (7.6%)	  L/CA	   1	   (3.3%)	   0	   (0.0%)	   1	   (7.1%)	   0	   (0.0%)	   2	   (2.5%)	  
Metastatic	  stage	   	   	   	   	   	   	   	   	   	   	  M0	   26	   (86.7%)	   6	   (85.7%)	   8	   (57.1%)	   18	   (64.3%)	   58	   (73.4%)	   0.09	  M1-­‐3	   4	   (13.3%)	   1	   (14.3%)	   6	   (42.9%)	   10	   (35.7%)	   21	   (26.6%)	  	  
Independent	  validation	  data	  set	  (Northcott	  et	  al.	  2009)	  
	   Medulloblastoma	  Subtypes	   Fisher’s	  
exact	  test	  Variable	   SHH	   WNT	   Group	  C	   Group	  D	   All	  28	   (31.1%)	   7	   (7.8%)	   25	   (27.8%)	   30	   (33.3%)	   90	   (100.0%)	   P	  
Age,	  years	   	   	   	   	   	   	   	   	   	   	   	  ≤3	   13	   (46.4%)	   1	   (14.3%)	   5	   (20.0%)	   1	   (3.3%)	   20	   (22.2%)	   <0.01	  4-­‐17	   8	   (28.6%)	   6	   (85.7%)	   20	   (80.0%)	   28	   (93.3%)	   62	   (68.9%)	  ≥18	   7	   (25.0%)	   0	   (0.0%)	   0	   (0.0%)	   1	   (3.3%)	   8	   (8.9%)	  
Gender	   	   	   	   	   	   	   	   	   	   	   	  Female	   16	   (57.1%)	   3	   (42.9%)	   7	   (28.0%)	   9	   (30.0%)	   35	   (38.9%)	   0.11	  Male	   12	   (42.9%)	   4	   (57.1%)	   18	   (72.0%)	   21	   (70.0%)	   55	   (61.1%)	  
Histology	   	   	   	   	   	   	   	   	   	   	   	  Classic	   17	   (60.7%)	   7	   (100.0%)	   20	   (80.0%)	   24	   (80.0%)	   68	   (75.6%)	   0.13	  MBEN/	  desmoplastic	   10	   (35.7%)	   0	   (0.0%)	   3	   (12.0%)	   3	   (10.0%)	   16	   (17.8%)	  L/CA	   1	   (3.6%)	   0	   (0.0%)	   2	   (8.0%)	   3	   (10.0%)	   6	   (6.7%)	  Abbreviations:	  MBEN,	  medulloblastoma	  with	  extensive	  nodularity;	  L/CA,	  large	  cell	  /	  anaplastic;	  SHH,	  sonic	  hedgehog	  pathway.	  
 
Our collaborators from Toronto (group of Dr. Michael Taylor) provided their 
published miRNA dataset (Northcott et al. 2009) as a validation data set for this 
study. In the Northcott study, 90 medulloblastoma samples were analyzed on a 
different miRNA microarray platform (Northcott et al. 2009)(Table 2A).  
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2.2.2	  MicroRNA	  preserved	  total	  RNA	  preparation	  
 All tissue samples were snap frozen immediately upon surgical resection. 
Frozen tissues were homogenized with a Micro-Disemebrator (B.Braun Biotech 
International, Melsungen, Germany) into fine powder under low temperature. 
Homogenized frozen tissue was digested with 700 µl Qiazol solution and miRNA 
preserved total RNA was extracted by using the miRNeasy kit (Qiagen, Hilden, 
Germany) following the manufacturer’s instruction. All RNA samples were eluted 
in 30 µl RNase free water.  
RNA concentrations were determined by NanoDrop ND-1000 spectrometer 
(NanoDrop, Wilmington, USA) measurement. RNA quality was assessed by use 
of the RNA 6000 Nano kit (Agilent Technologies, Santa Clara, USA). Only 
samples with a RIN (RNA integrity number) higher than 8.0 wereused for further 
experiments (Schroeder, Mueller, et al. 2006) (Appendix 8.1).  
2.2.3	  MicroRNA	  microarray	  and	  bioinformatics	  analysis	  
The genome-wide microRNA expression prolife of the screening set was 
revealed by hybridization to the Illumina microRNA DASL microarray V2 
containing 1146 Human miRNAs(Illumina, San Diego, USA). Raw data were 
normalized by quantile normalization by using the Illumina software BeadStudio 
(ver.3). Normalized values were log2 transformed. Unsupervised hierarchical 
clustering (HCL) was performed using Ward’s linkage and dissimilarity based on 
Euclidian distance. Cluster reliability was assessed using a bootstrap-based 
approach (Suzuki et al. 2006), which gives approximately unbiased (AU) 
probabilities. Principal component analysis (PCA) was applied as additional 
unsupervised approach. Significance Analysis of Microarrays (SAM) was 
performed with the TMEV software (ver. 4.3) (http://www.tm4.org/mev/) testing 
each miRNA separately for difference in expression between SHH and non-SHH 
tumors. MiRNAs with a false discovery rate (FDR) equals to 0 were selected 
identifying miRNA signatures best disrciminating between two predefined 
subgroups.  
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2.2.4	  Quantitative	  real-­‐time	  PCR	  and	  statistic	  analysis	  
TaqMan MicroRNA Assays (Applied Biosystems, Foster City, USA) were 
used to verify the expression levels of candidate miRNAs (hsa-miR-182, ABI 
assay ID 00597; hsa-miR-183, ABI assay ID 000484; hsa-miR-96, ABI assay ID 
000434). Fifty ng of good quality (RIN>8.0) total RNA was use for the stem-loop 
reverse transcription (RT) of the mature miRNA. Stem-loop cDNA was then 
synthesised with the looped RT primer specifically binding to the distinct miRNA. 
Finally, quantitative real-time PCR (QRT-PCR) was performed in triplicates 
using florescence labelled TaqMan probes on an ABI 7900HT PCR system. 
Expression levels of miRNAs were normalized to two house keeping small 
RNAs (HKsRNAs) RNU6B (ABI assay ID 001093) and RNU66 (ABI assay ID 
001002) and the relative expression ratio further compared with a pooled normal 
cerebellum (NCB) total RNA (Clontech Laboratories, Inc.) comprised of a pool of 
24 donors.  
	  
Figure	  2-­‐1.	  MicroRNA	  TaqMan	  QRT-­‐PCR	  chemistry.	  	  (Image	  from	  Applied	  Biosystems	  website,	  	  http://www.appliedbiosystems.com/absite/us/en/home.html)	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The raw read value from the real-time PCR machine is Ct (cycle threshold), 
which is defined as the number of cycles required for the fluorescence signal to 
cross the threshold (after background subtraction): The higher the quantity, the 
lower the observed Ct value. The relative amount of the candidate miRNA is 
calculated by the equation (2- ΔΔCt), where, 
ΔΔCt = (Ct tissue – Ct house keeping) – (Ct NCB-Ct house keeping) 
While 2-0 = 1 (value of NCB minus itself), thus we have a comparative basal 
value of NCB of 1 and counted values larger than 1 as upregultaion, whereas 
lower than 1 was defined as downregulation.. After log2-transformation, up- or 
downregulation of the candidate miRNAs is defined as positive (>0) or negative 
(<0) log2-ratio, respectively. 
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2.2.5	  Statistic	  analysis	  
Correlation between miRNA expression and QRT-PCR values was assessed 
with Spearman’s correlation coefficient (Spearman’s rho) including confidence 
intervals based on Fisher’s z-transformation. The distribution of candidate 
miRNA expression was tested for differences in tumor location, stage, location, 
and biological core subgroups with the two-sided Mann-Whitney test. Fisher’s 
exact test was used to compare clinical-pathological characteristics between 
tumor variants. In vitro experiments with scratch assays and 3D microchannel 
migration assays were analyzed comparing the ratio of final and initial 
measurements with the control group. For growth rate experiments, the ratio 
between growth rate at each time point and growth rate at day 1 was compared 
with the control group. Non-parametric relative effects between groups were 
tested using Dunnett contrasts (many-to-one comparison) with p-values being 
adjusted for multiple testing (Hasler et al. 2008). 
P-values below 0.05 were considered statistically significant. Statistical 
analyses were performed with the R/Bioconductor software environment, 
version 2.13/2.8 using the add-on R package pvclust (R Development Core 
Team 2011) and nparcomp (Munzel et al. 2001). 
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2.2.6	  Cell	  culture	  
The QRT-PCR results showed high, moderate, and low expression of miRNA 
candidates in medulloblastoma cell lines DAOY (Cat#HTB-186, ATCC), 
D458Med (kindly provided by Dr. Darell D. Bigner, Duke University North 
Carolina, USA) and Med8A (kindly provided by Dr. Michael D. Taylor, University 
of Toronto, Canada) respectively. As a result, these cell lines were chosen for 
further in vitro functional studies. (Fig. 2-2).  
D458Med is cultured in Improved MEM Zn++ option medium (Invitrogen, 
Karlsruhe, Germany) supplemented with 20% fetal bovine serum (FBS), 
whereas DAOY and Med8A are cultured in Dulbecco´s Modified Eagle Medium 
(DMEM) (Sigma Aldrich, Munich, Germany) supplemented with 10% FBS. All 
cultures were maintained at 5% CO2 and cells were split at a ratio of 1:5 
approximately every week.  
	  
Figure	   2-­‐2.	   Expression	   levels	   of	   the	   three	   miRNA	   candidates	   in	  medulloblastoma	  cell	  lines.	  The	  three	  selected	  cell	  lines,	  D458Med,	  DAOY,	  and	  Med8A	   showed	   high,	   intermediate	   and	   low	   expression	   of	   candidate	  miRNAs,	  respectively.	  The	  expression	  level	  of	  miR-­‐96	  in	  Med8A	  cells	  was	  very	  close	  to	  NCB,	  both	  had	  Cts	  >40.	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2.2.7	  Overexpression	  vector	  construction	  
PCR fragments containing the whole pri-miRNA sequence of the candidate 
miRNAs were amplified with specific primers (Table 2B). All 5`-ends of the 
primers were added with designated restriction sites. ThepCMX-PL1 vector 
(pCMX) used for miRNA overexpressionwas a generous gift from Dr. Roland 
Schüle (Women's Hospital and Center for Clinical Research, Medical School 
Freiburg, Germany) (Pscherer et al. 2006). 
	  
Table	  2B	  PCR	  primer	  sequences	  Primer	  code	   Primer	  sequence	  (5`~3`)	   Tm	   Product	  size	  miR182-­‐F1	   CAGAATTCGCCTGGACCATCCTAACTGT	   59.0	   296bp	  miR182-­‐R1	   CTGCTCGAGCTCTGCCACTACCCAGCAGT	   59.0	  miR183-­‐F1	   CAGGATCCCTTGTGAAGAGGTGGGATGG	   60.5	   325bp	  miR183-­‐R1	   CTGCTCGAGTTCCGACGTCTAGGAGCACT	   60.0	  miR96-­‐F1	   CAGAATTCGCCTTGAGTGCTCCTAGACG	   60.0	   360bp	  miR96-­‐R1	   CTGCTCGAGGTGAGGAGGCCTTGAGGAG	   59.9	  Restriction	  Enzyme	  sequences	  at	  5`	  ends:	  CAGAATTC	  (EcoR1);	  	  CTGCTCGAG	  (Xho1);	  CAGGATCC	  (BamH1).	  	  	  
 
Genomic DNA used as PCR template was isolated form cultured cell pellets 
using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) after RNase A 
(Qiagen, Hilden, Germany) and proteinase K (Roche Diagnostics, Mannheim, 
Germany) digest overnight.  
Both the vector and PCR products were digested with restriction enzymes 
overnight (EcoR1, 10U; Xho1, 10U; BamH1, 20U). Digested products were 
separated by agarose gel (Sigma Aldrich, Munich, Germany) to confirm the 
complete digestion. Separated products were cut out from the agarose gel and 
cleaned up using the QiaQuick gel extraction kit (Qiagen, Hilden, Germany) and 
the ligation carried out with 1U T4 ligase (Fermentas, St. Leon-Roth, German) 
and a mixture of vector and PCR product in a ratio of 1:10 in a final volume of 15 
µl by incubation overnight at 8°C. 
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The completed ligation product was mixed with One Shot TOP10 chemically 
competent cells (Invitrogen, Karlsruhe, Germany), incubated on ice for 30 
minutes, then heat shocked in a 42°C water bath for 30 seconds. SOC medium 
(Invitrogen, Karlsruhe, Germany) was added to competent cells and incubate at 
37°C with 250 rpm shaking. Competent cells were evenly spread on a pre-
warmed agar plate with 100mg/ml ampicillin (Roche Diagnostics, Mannheim, 
Germany) and incubated overnight for the competent cells to grow. 
Colonies were inoculated in LB-broth with 100 mg/ml ampicillin at 37°C with 
250rpm shaking. Plasmid DNA was isolated from the inoculated product next 
day using the QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany). The 
sequences of the vector containing plasmid DNA were verified by BigDye 
Terminator Sequencing (Applied Biosystems, Foster City, USA) on a 3130 
Genetic Analyzer (Applied Biosystems, Foster City, USA). Vectors with the 
correct sequence of the insert fragment were used for the transfection 
experiments. 
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2.2.8	  Stable	  overexpression	  and	  transient	  knockdown	  of	  miRNA	  
candidates	  
Selected cell lines were harvested and adjusted to a cell density of 8x104 
cell/ml using the Vi-CELL XR 2.03 cell counter (Beckman Coulter, Krefeld, 
Germany). Then 500 µl (adherent cells, DAOY / Med8A) or 750 µl (suspension 
cells, D458Med) of cell suspension were seeded in a 6-well plate containing 
culture medium without antibiotics one day before transfection. The next day,    
1 µg of plasmid DNA (candidate miRNA containing pCMX or empty pCMX 
vector only) and 1.5 µl Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) 
were diluted with 50 µl Opti-MEMI Reduced-Serum Medium (Gibco Invitrogen, 
Karlsruhe, Germany), respectively. The two solutions were incubated at room 
temperature for 10 minutes and then mixed together and incubated at room 
temperature again for 20 minutes to generate nucleic acid-Lipofectamine 
complexes. The complexes were added directly to cultured cells in the 6-well 
plate and incubated at 37°C and 5% CO2 for 24 hours. 
After a 24-hour-incubation, the culture medium was changed to selective drug 
medium containing 25 mM (DAOY) or 30 mM (D458Med and Med8A) zeocin 
(Invitrogen, Karlsruhe, Germany) for stable clone selection. While control cells 
with mock-transfection (transfection done with lipofectamin only, without any 
plasmid DNA) died rapidly, zeocin resistant cells in the transfection 
samplesgrew normally in the selective drug medium. 
Five to eight single colonies were picked and first grew in 24-well plates and 
progressively expanded to 75 cm2 flasks whenever 90% confluence was 
reached. Expression levels of candidate miRNAs were checked by QRT-PCR, 
and the two colonies with the highest overexpression of the respective candidate 
miRNA without influencing the expression of other cluster members were 
selected for further in vitro functional studies. (Fig. 2-3)  
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Figure	  2-­‐3.	  QRT-­‐PCR	  confirming	  overexpression	  of	  candidate	  miRNAs	   in	  stably	   transfected	   medulloblastoma	   cell	   lines	   without	   influencing	   the	  expression	   levels	   of	   other	   cluster	  members.	   Baseline	  miR-­‐96	   expression	  was	   too	   low	   to	   be	   detected	   in	   Med8A,	   and	   there	   was	   no	   successfully	  transfected	  Med8A	  clone	  for	  miR-­‐96	  retrieved	  after	  several	  trials.	  	  	  
The same cell culture conditions as for the overexpression were used for the 
transient knockdown (KD) of miRNAs. Nucleic acid-Lipofectamine complexes 
were prepared with Ambion Anti-miR miRNA Inhibitors (hsa-miR-182, AM12369; 
hsa-miR-183, AM12830; hsa-miR-96, AM10422) (Applied Biosystems, Foster 
City, USA) and Lipofectamin 2000. These small and chemically modified single-
stranded RNA (ssRNA) molecules, also called small interfering RNAs (siRNAs) 
are designed to specifically bind to and inhibit the biogenesis of endogenous 
miRNAs. The final concentration of anti-miRs was adjusted to 50nM in 500µl 
culture medium in 6-well culture plates. In parallel, the transfection efficiency 
was monitored by transfection with 25nM of BLOCK-iT Alexa Fluor Red 
Fluorescent Control (Invitrogen, Karlsruhe, Germany), under a fluorescence 
microscope with an emission light at 565nm, excited by 555nm light source after 
6 to 24 hours incubation. 
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Related in vitro functional assays were made after 24 hours of knockdown. 
Expression levels of candidate miRNAs were also checked by QRT-PCR after 
KD treatment. Expression levels of targeted miRNAs were reduced by at least 
30% without off target effects on other miRNAs within the mir-183 cluster (Fig. 2-
4).  	  	  
	  
Figure	  2-­‐4.	  QRT-­‐PCR	  showing	  expression	  levels	  of	  candidate	  miRNA	  upon	  anti-­‐miRs	  treatment	  for	  24	  hours.	  As	  for	  the	  overexpression	  experiments,	  the	  expression	  of	  miR-­‐96	  was	  too	  low	  to	  be	  detected.	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2.2.9	  Scratch	  assay	  	  
Only cell lines growing in a monolayer may be investigated by this functional 
assay. DAOY and Med8A cells selected for this study were seeded at 90% 
confluence on chambered cover glass (Nunc Thermo Scientific, Langenselbold, 
Germany). After the cells had adhered firmly on the glass, the medium was 
changed to serum free medium. After serum starvation overnight (>16 hours), 
an artificial scratched wound was introduced with a P10 pipette tip in the middle 
of the chamber.  
Time-lapse pictures at every hour were captured with a phase-contrast live-
cell imaging system with humidified chamber at 37°C (Zeiss Cell Observer; Carl 
Zeiss, Jena, Germany).  
Picture at time points 0h and 12h were used to determine the wound healing 
speed (migration speed towards each other) of the tested cell line. Three 
different positions along the wound were captured and the widths of the wound 
were measured by using the Zeiss AxioVision image analysis software. 
Differences of the wound width between time point 0h and 12h of each 
experimental condition were calculated. For each experimental condition, we 
calculated the ratio between the tested cell line against the control cell line (cell 
line transfected with empty vector or treated with scrambled siRNA control).  
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2.2.10	   Boyden	  chamber	  assay	  
Two different assay platforms were used in this study. The migration ability of 
medulloblastoma cells was measured in transwells with 8µm-pore polycarbonate 
membrane insert (Corning Sigma Aldrich, Munich, Germany). The invasion 
ability was determined by using BD BioCoat Matrigel invasion chambers (BD 
Biosciences, Heidelberg, Germany). After serum starvation for 24h cells were 
harvested and resuspended in serum free medium. Cell density was determined 
by using a Vi-CELL XR 2.03 cell counter (Beckman Coulter, Krefeld, Germany). 
1x105 cell or 5x105 cells were seeded in the upper reservoir of the migration or 
invasion chambers, respectively. Normal culture medium with FBS was added in 
the lower reservoir as a chemoattractant. After 16 to 24 hours of incubation, 
migrated cells were attached to the bottom of the transwell membrane. A cotton 
swab was used to wipe off the un-migrated cells still remaining on the upper 
surface of the transwell membrane. Migrated cells on the bottom of the transwell 
membrane were fixed with methanol, stained with heamatoxlin, washed in water 
and dehydrated with 70% and 100% ethanol, respectively. After air drying 
overnight, the transwell membrane was removed from the plastic insert and 
mounted on a glass slide for cell counting.  
Cell counting was made on an Axioskop 40 microscope (Carl Zeiss, Jena, 
Germany) using the 65X objective (Fig. 2-5). Total cell number and total number 
of microscopic field observed were recorded. Relative cell count (number of cell 
per microscopic field) of each experimental condition was compared with the 
respective control.  	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Figure	   2-­‐5.	   Microscopic	   view	   of	   the	   polycarbonate	   membrane	   from	   the	  migration	  assay	  insert	  (65X).	  Left	  picture:	  upper	  side	  of	  the	  membrane	  showing	  8μm	  pores	  in	  a	  smooth	  circular	  shape.	  Right	  picture:	  the	  edges	  of	  the	  pores	  on	  this	  side	  are	  showing	  an	  irregular	  shape	  with	  migrated	  cells	  in	  the	  middle	  of	  the	  image.	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2.2.11	   3D	  microchannel	  assay	  
Poly(dimethylsiloxane) (PDMS) based microchannel chips were kindly 
provided by Dr. Ralf Kemkemer (Max Planck Institute for Intelligent Systems, 
Stuttgart, Germany). Channel structures with the dimensions of 5x11x300 µm, 
7x11x300 µm, and 10x11x100 µm (WxHxL) were bio-functionalized prior to use 
by incubation with a 50µg/ml fibronectin solution. Chips were fixed on a Teflon 
holder and 2x105 cells were seeded on the chip in close proximity to the 
channels. After cells were attached on the chip, the chamber was filled with 
culture medium and live-cell imaging was started.  
Phase-contrast time-lapse pictures of multiple positions were captured every 
10 minutes with an automated inverted microscope (Zeiss Cell Observer; Carl 
Zeiss, Jena, Germany) equipped with a heated and air-humidified chamber. 
Images were recorded and processed with the Zeiss AxioVision image analysis 
software and ImageJ (http://rsbweb.nih.gov/ij/).  
Cell behavior was analyzed and categorized into three activities: penetration, 
invasion, and permeation. While “penetration” refers to cells that penetrate the 
channels with their cytoplasm to a depth of at least 20 µm, but did not 
completely enter into the channel, cells that completely entered the channel 
structure and stopped there or turned around back to the starting point or still 
moving within the channel were called “invasion”. Whenever cells migrated 
completely to the other side of the channel, this was counted as “permeation” 
(Rolli et al. 2010).  
After assessing cell activities in each individual channel overnight, the 
invasiveness of the cells is defined as the percentage of invasive activity 
(invasion and permeation) of all cells that were trying to enter the channels. The 
relative invasiveness change was set as the ratio of invasiveness of tested cell 
lines against the respective control cell line (empty vector transfected or 
scrambled siRNA treated) to facilitate the comparison with all other experiments 
in the study. 
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2.2.12	  Meduloblastoma	  experiments	  in	  vivo	  
5x105 DAOY cells with stable overexpression of miR-182 or control vector, 
respectively, were injected into the left cerebellar hemisphere of CB17/SCID 
mice (Charles River Laboratories) using a stereotact. After injection all mice 
were monitored by magnetic resonance imaging (MRI) every two months. All 
MRI examinations were performed using a custom-developed transmit/receive 
small animal coil in a conventional whole-body 1.5 T MRI scanner (Symphony, 
Siemens, Erlangen). Lesions including brain tumors were localized on T2w 
turbospinsecho images (TE: 109 ms; TR: 4000; FoV: 40x30 mm; matrix: 128; 
voxel size: 0,3x0,3x1 mm³). Mice were sacrificed once a tumor was discovered, 
and tissue was collected for Haematoxylin & eosin staining and analysed by a 
experienced neuropathologist.  
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3	   RESULTS	  
One hundred and eleven medulloblastoma tissues were included in this study 
aiming to discriminate medulloblastoma subgroups based on their miRNA 
signatures. Significant miRNA candidates were then selected for functional 
studies, thus to clarify the role of candidate miRNAs in medulloblastoma 
development, maintenance, and dissemination.  
3.1	   MicroRNA	  profiling	  and	  candidate	  microRNA	  
identification	  
Investigation of genome-wide miRNA expression profiles in 32 primary 
medulloblastomas was done on Illumina microRNA DASL arrays. Raw data 
were normalized by quantile normalization and log2-transformed. Micro-RNA 
signatures were integrated with molecular subgroup information of the 
medulloblastoma tissue samples, which were obtained in a previous study 
(Remke et al. 2011). 
The Unsupervised hierarchical clustering (HCL) identified three subgroups in 
the screening set based on miRNA profiles: (i) SHH-driven medulloblastomas 
were all grouped into an individual cluster, (ii) group C and group D 
medulloblastoma tumors comprised the second cluster, and (iii) the third cluster 
was consisting of all WNT medulloblastomas and three samples from each of 
the other groups (Ward’s linkage, euclidian distances) (Fig.3-1).  
 Principal component analysis (PCA), an alternative method for unsupervised 
classification into subgroups substantiated the findings from the HCL analysis 






Figure	   3-­‐1.	   Unsupervised	   hierarchical	   clustering	   (HCL)	   of	   the	   screening	  set	  (n=32).	  HCL	  clearly	  separated	  the	  screening	  cohort	  into	  three	  clusters	  with	   high	   reliability.	   Clinico-­‐pathological	   characteristics	   are	   summarized	  under	  the	  heatmap.	  Age	  groups	  include	  infants	  (≤	  3	  years,	  white),	  children	  (4-­‐17,	   red),	   and	   adults	   (≥	   18	   years,	   black).	   Gender	   includes	   females	  (white)	   and	   males	   (black).	   Location	   includes	   hemispheric	   (white)	   and	  midline	  (black).	  Metastatic	  stage	  (M	  stage)	  includes	  M0	  (white)	  and	  M1-­‐3	  (black).	  Histology	  includes	  classic	  (white),	  large	  cell	  /anaplastic	  (red),	  and	  MBEN/desmoplastic	  (black).	  Molecular	  subgroups	  (Mol.	  Subtype)	  include	  SHH	  (red),	  WNT	  (blue),	  group	  C	  (yellow),	  and	  group	  D	  (green).	  This	  color	  scheme	  applies	  to	  all	  figures	  in	  this	  dissertation.	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When trying to delineate the fundamental expression differences between 
SHH- and non-SHH medulloblastomas by Significance Analysis of Microarrays 
(SAM), a robust 26-miRNA signature (Table 3A) was obtained (Fig.3-3). SHH 
medulloblastomas remain in an individual cluster. The remaining tumors were 
observed to fall into two additional clusters, one of them mainly consisting of 
group D tumors and the second one being mainly comprised of WNT, group C 
and group D tumors. 
	  
Table	  3A.	  The	  26-­‐miRNA	  signature	  from	  SAM	  analysis	  	   miRNA	   Fold	  change	   	  1	   hsa-­‐miR-­‐96	   0.1604	   Downregulation	  in	  SHH-­‐MB	  
2	   hsa-­‐miR-­‐183	   0.2448	  3	   hsa-­‐miR-­‐455	   0.2840	  4	   hsa-­‐miR-­‐182	   0.3054	  5	   hsa-­‐miR-­‐138	   0.3944	  6	   hsa-­‐miR-­‐204	   0.4328	  7	   hsa-­‐miR-­‐490	   0.4808	  8	   hsa-­‐miR-­‐582	   0.5004	  9	   hsa-­‐miR-­‐135b	   0.5985	  10	   hsa-­‐miR-­‐181c	   0.6085	  11	   hsa-­‐miR-­‐491	   0.6958	  12	   hsa-­‐miR-­‐338	   0.6990	  13	   hsa-­‐miR-­‐331	   0.8725	  14	   hsa-­‐miR-­‐143	   1.3859	   Upregulation	  in	  SHH-­‐MB	  
15	   hsa-­‐miR-­‐511	   1.8112	  16	   hsa-­‐miR-­‐146a	   1.9267	  17	   hsa-­‐miR-­‐20b	   1.9398	  18	   hsa-­‐miR-­‐363	   2.0014	  19	   hsa-­‐miR-­‐92b	   2.0410	  20	   hsa-­‐miR-­‐28	   2.0642	  21	   hsa-­‐miR-­‐214	   2.0664	  22	   hsa-­‐miR-­‐199a	   2.2310	  23	   hsa-­‐miR-­‐221	   2.3306	  24	   hsa-­‐miR-­‐200b	   2.5287	  25	   hsa-­‐miR-­‐155	   2.5746	  26	   hsa-­‐miR-­‐10a	   6.7915	  MB	  :	  medulloblastoma
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Figure	   3-­‐3.	   Supervised	   HCL	   using	   the	   26-­‐miRNA-­‐signature	   in	   the	  screening	   cohort.	   Primary	  medulloblastoma	   samples	  were	   clustered	   into	  three	  groups	  SHH	  medulloblastomas,	  a	  cluster	  that	  only	  contained	  group	  D	  medulloblastomas,	   and	   a	   third	   cluster	   containing	   all	   group	   C	   and	   WNT	  medulloblastomas	  as	  well	  as	  some	  additional	  group	  D	  tumors.	  Dark	  green	  boxes	   indicate	   the	   three	   candidate	   miRNAs,	   which	   show	   high,	  intermediate	  and	  low	  expression	  in	  the	  three	  clusters,	  respectively.	  	  	  
Applying the same miRNA signature to our validation dataset, which was 
obtained in a completely non-overlapping cohort in a different lab on a different 
microarray platform (Nortchott, 2009), SHH medulloblastomas could again be 
readily separated from non-SHH medulloblastomas. The remaining samples 
were separated into two clusters again, one of them mainly consisting of group 
D medulloblastomas, and the other one including WNT and group C tumors in 





Figure	  3-­‐4.	  Supervised	  HCL	  of	  the	  validation	  set	  (n=90)	  using	  the	  miRNA	  signature	  obtained	   in	   the	  screening	  cohort.	   In	   the	  validation	  cohort,	  only	  25/26	  signature	  miRNAs	  were	  included	  since	  miR-­‐92b	  expression	  was	  not	  determined	   in	   the	   validation	   dataset.	   All	   SHH	   medulloblastoma	   tumors,	  with	  only	  one	  outlier,	  grouped	   into	   the	  cluster	  on	  the	   left	  hand	  side.	  The	  cluster	   in	   the	  middle	   is	  mainly	   comprised	  of	   group	  D	  medulloblastomas,	  whereas	   group	   C	   and	  WNT	  medulloblastomas	  were	  mainly	   found	   in	   the	  third	   cluster.	   Dark	   green	   boxes	   indicate	   three	   candidate	   miRNAs,	   the	  retina-­‐specific	  miRNAs.	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From the 26-miRNA signature, retina specific miRNAs, hsa-miR-182 (miR-
182), hsa-miR-183 (miR-183), and hsa-miR-96 (miR-96), were the most 
differentially regulated miRNAs (Table 3A). Based on this, we focused our 
further investigations of this miRNA cluster. In the validation dataset, however, 
the same strong association with disease subgroups was only observed for miR-
182 and miR-183, but not for miR-96 (Fig.3-5).  	  
	  




3.2	   Technical	  validation	  of	  microarray	  data	  
Taqman based QRT-PCR was used to further investigate the expression 
levels of candidate miRNAs, miR-182, miR-183, and mir-96, in a cohort of 111 
medulloblastoma samples consisting of the 32 samples (previously analyzed on 
the microarray) as well as 79 non-overlapping cases. Comparing the expression 
levels obtained by microRNA microarrays with the results from the QRT-PCR, 
results were highly reproducible (Spearman’s rho>0.9, p<0.0001) (Fig.3-6).  	  
	  	  
Figure	   3-­‐6.	   Correlation	   of	   QRT-­‐PCR	   results	   with	   microRNA	   microarray	  results	   Showing	   a	   good	   technical	   reproducibility	   of	   the	  microarray	   data	  (p<0.0001)	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 QRT-PCR results from the QRT-PCR validation data set (n=79) confirmed 
our findings obtained in the screening cohort, namely the same characteristic 
expression patterns among medulloblastoma subgroups (p<0.0001) (Fig.3-7).  	  
	  




Integrating QRT-PCR results with clinico-pathological parameters, the 
expression of candidate miRNAs was signaficantly associated with tumor 
location and metastatic stage (Fig.3-8). Midline medulloblastomas showed a 
significantly higher expression of all candidate miRNAs in comparison with 
hemispheric tumors. Comparing expression levels with metastatic stage, miR-
182 and miR-96 were found to be significantly higher expressed in metastatic 
medulloblastoma (Fig.3-8). No significant correlation was found between 
candidate miRNA expression patterns and patient age, gender, overall survival 




Figure	   3-­‐8.	   Expression	   of	   candidate	   miRNAs	   is	   associated	   with	   tumor	  location	  and	  metastatic	  stage.	  All	  candidate	  miRNAs	  are	  higher	  expressed	  in	   midline	   medulloblastoma,whereas	   miR-­‐182	   and	   miR-­‐96	   are	  significantly	  associated	  with	  metastatic	  stage.	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3.3	   In	  vitro	  functional	  studies	  
A robust miRNA signature discriminated SHH medulloblastoma from the 
other subgroups in both the screening data set and the validation data set with 
the miR-183~96~182 cluster being the most differentially expressed cluster 
between these two groups. After confirming this expression pattern in a larger 
test set, we especially focused on miR-182, because it showed clear association 
with important clinical determinants, mostly metastatic dissemination. However, 
all three members of this cluster were further subjected to in vitro functional 
studies to assess the importance and specific role of each candidate miRNA in 
medulloblastoma 
To investigate the functional roles of these retina specific miRNAs, we 
generated stably transfected medulloblastoma cell lines showing constitutive 
overexpression of each candidate miRNA. Transient knockdown of individual 
miRNAs complemented our functional investigations. 
Unfortunately, the stable transfection of miR-96 was not successful in the 
medulloblastoma cell line Med8A despite several trials. We failed to retrieve any 
single colony from the zeocin containing selective medium after transfection. As 
a result, only 2 Med8A stable cell lines with miR-182 or miR-183 overexpression 
are presented. Two other medulloblastoma cell lines, DAOY and D458 Med, 
were successfully transfected with all three miRNAs. 
3.3.1	  Proliferation	  assay	  (MTS)	  	  
We used a non-radioactive colorimetric cell proliferation assay (MTS) to 
assess the metabolic activities of medulloblastoma cells after stable transfection 
or transient knockdown of candidate miRNAs.  
Optical density (OD) at day 1 was used as baseline value; thus, all following 
data points are relative to day 1. MTS results obtained in the three medullo-
blastoma cell lines showed that neither stable overexpression nor transient 
knockdown of any of the candidate miRNAs had a significant impact on the 






Figure	   3-­‐9.	   Proliferation	   assay	   (MTS)	   indicating	   that	   neither	   over-­‐expression	   nor	   knockdown	   of	   any	   of	   the	   three	   candidate	  miRNAs	   had	   a	  significant	   impact	   on	   the	   metabolic	   activity	   of	   medulloblastoma	   cells.	  Metabolic	  activities	  of	   stably	   transfected	  cell	   lines	  were	  compared	   to	   the	  respective	  empty	  vector	   (pCMX)	  controls	  over	  7	  days	  (overexpression	  of	  miR-­‐182	   in	   dark	   blue,	   miR-­‐183	   in	   light	   blue,	   and	   miR-­‐96	   in	   purple).	  Bottom	   panels	   illustrate	   the	   growth	   rate	   of	   three	   medulloblastoma	   cell	  lines	  after	  transient	  knockdown	  of	  candidate	  miRNAs.	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3.3.2	  Scratch	  assay	  
Whereas proliferation was not affected by stable overexpression or transient 
knockdown of retinal miRNAs in all selected medulloblastoma cell lines, another 
interest of this study is the role of the candidate miRNAs in medulloblastoma cell 
migration. Therefore, different in vitro migration assays were applied.  
The scratch assay is a time- and cost-effective in vitro functional assay to test 
the migratory speed of a cell line. The main limitation of this assay is that it is 
restricted to cells growing in a monolayer. 
Two of the three medulloblastoma cell lines included in our study, DAOY and 
Med8A, grow in a monolayer and were subjected to scratch assays upon stable 
overexpression and transient knockdown of candidate miRNAs. After 12 hours 
incubation, two different DAOY clones with stable miR-182 overexpression 
(DAOY-182K1, DAOY-182K2) showed an at least 4-fold increase in migration 
speed when compared to DAOY transfected with empty vector (DAOY-
pCMX)(Fig.3-10). 
Overexpression of miR-183 in DAOY (DAOY-183K1, DAOY-183K2), in 
contrast, did not lead to obvious differences in the migration speed (Fig.3-10) 
neihter did miR-96 overexpression. (Fig.3-11) 
Transient knockdown of either miR-182 or miR-183 in DAOY cells revealed a 
strong reduction in migration speed by around 80% relative to the scrambled 
negative control (siControl). Knocking down miR-96 also excerted a moderate 






Figure	   3-­‐10.	  Phase	  contrast	   images	  show	  the	   time-­‐lapse	  captures	  of	   the	  scratch	   assay	   at	   0h	   and	   12h.	   More	   than	   4	   fold	   increment	   of	   migration	  speed	  was	  observed	  in	  the	  two	  miRNA-­‐182	  over-­‐expressing	  DAOY	  clones	  (182K1,	   182K2)	   compared	   to	   empty	   vector	   transfected	   DAOY	   cells	  (pCMX).	   Both	   DAOY	   single	   colonies	   with	   miR-­‐182	   overexpression	   could	  heal	   the	   whole	   scratch	   within	   12	   hours.	   Scale	   bar:	   100	   μm.	   Error	   bars	  indicate	  the	  mean±SD	  of	  three	  independent	  experiments.	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Figure	   3-­‐12.	   Scratch	   assay	   showed	   similar	   reduction	   of	   migration	   of	  DAOY	   after	   transient	   knockdown	   of	   the	   candidate	   miRNAs.	   The	   images	  above	  show	  the	  time-­‐lapse	  pictures	  of	  scratch	  assay	  of	  DAOY	  cell	  24	  hours	  after	   transient	   siRNA	   treatment.	   Scale	   bar:	   100	   μm.	   The	   bar	   chart	  underneath	  shows	  the	  dramatically	  reduced	  migration	  speed	  after	  siRNA	  treatment	   of	   DAOY	   cell.	   All	   error	   bars	   indicate	   the	   mean±SD	   of	   three	  independent	  experiments.	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Another medulloblastoma cell line, Med8A, which has the lowest expression 
levels of the three candidate miRNAs among all tested cell lines (Fig. 2-2) was 
also subjected to scratch assays upon miRNA overexpression. Overexpression 
of miR-182 in Med8A cells had a moderate effect of increased migration in 
Med8A cells, whereas Med8A cells overexpressing miR-183 showed no change 
in their migration phenotype As expected based on the low baseline expression 
of retinal miRNAs in this cell line, no change in the migration phenotype was 








3.3.3	  Boyden	  chamber	  assays	  
The upper and lower reservoirs of a Boyden chamber are separated by a 
pored membrane insert. For the migration assay, inserts with a plain 
polycarbonate membrane with 8 µm sized pores were used, whereas for the 
invasion assay, the membranes were coated with matrigel. Cells were seeded in 
the upper reservoir in serum free medium, whereas the lower reservoir was filled 
with complete growth medium. The number of cells in the lower reservoir after a 
defined incubation period indicates the migration or invasion ability of the tested 
cell line. 
Overall, the results of the Boyden chamber assays nicely confirmed 
observations from the scratch assays. DAOY cells with miR-182 overexpression 
showed an at least 2-fold increment of migration compared to empty vector in 
both the migration and invasion assays. Overexpression of miR-183 and miR-96 
also by Boyden chamber assay did not lead to a significant increment in cell 
migration and invasion. Again consistent with our previous results, we observed 
a significant reduction of cell migration upon siRNA knockdown of miR-182 In 
DAOY cells further substantiating the important function of miR-182 in 
medulloblastoma cell migration (Fig. 3-14) 
	  
	  
Figure	  3-­‐14.	  Boyden	  chamber	  assays	  confirmed	  that	  miR-­‐182	  expression	  is	   significantly	   associated	   with	   the	   migratory	   phenotype	   of	   DAOY	   cells.	  Overexpression	  of	  miR-­‐183	  and	  miR-­‐96	  did	  not	  change	  the	  invasion	  ability	  or	  migratory	  phenotype	  of	  DAOY	  cells.	  Transient	  knockdown	  (KD)	  of	  miR-­‐182	   significantly	   reduced	   DAOY	   cell	   migration.	   Error	   bars	   indicate	   the	  mean±SD	  of	  three	  independent	  experiments.	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Consistent with the scratch assay results, one of two miR-182 overexpressing 
Med8A clones (182K2) showed a higher cell migration and invasion in the 
Boyden chamber assays, whereas no difference was observed for the second 
miR-182 overexpressing clones, and for miR-96 or miR-183 overexpression 
(Table 3B) 	  
Table	  3B.	  Boyden	  chamber	  assay	  results	  –	  Med8A	  stable	  transfected	  cells	  	   Migration	  assay	   	   Invasion	  assay	  	   	  	   Index	   Field	  observed	   Cell	  count	   	   	  	   Index	   Field	  observed	   Cell	  count	  
Test	  1	  
pCMX	   0.00	   94	   0	   	   pCMX	   0.03	   79	   2	  182K1	   0.05	   87	   4	   	   182K1	   0.07	   84	   6	  182K2	   0.10	   87	   9	   	   182K2	   0.23	   80	   18	  183K1	   0.00	   94	   0	   	   183K1	   0.02	   88	   2	  183K1	   0.00	   92	   0	   	   183K2	   0.00	   86	   0	  
Test	  2	  
pCMX	   0.00	   97	   0	   	   pCMX	   0.00	   81	   0	  182K1	   0.00	   82	   0	   	   182K1	   0.04	   82	   3	  182K2	   0.03	   80	   2	   	   182K2	   0.09	   77	   7	  183K1	   0.00	   92	   0	   	   183K1	   0.00	   82	   0	  183K2	   0.00	   89	   0	   	   183K2	   0.00	   89	   0	  
Test	  3	  
pCMX	   0.01	   92	   1	   	   pCMX	   0.03	   79	   2	  182K1	   0.01	   92	   1	   	   182K1	   0.07	   84	   6	  182K2	   0.00	   96	   0	   	   182K2	   0.15	   80	   12	  183K1	   0.00	   88	   0	   	   183K1	   0.02	   88	   2	  183K2	   0.02	   85	   2	   	   183K2	   0.00	   86	   0	  Field	  observed:	  number	  of	  microscopic	  view	  (63X	  objective)	  observed.	  Index	  =	  Cell	  count	  /	  Fields	  observed	  	  	  	  
The third medulloblastoma cell line, which was subjected to Boyden chamber 
assays upon knockdown and overexpression of retinal miRNAs, was D458Med, 
a cell line that is growing half in suspension and half adherent. Boyden chamber 
assays showed a significant increase of migration and invasion upon miR-182 
overexpression in D458Med cells (182K1, 182K2 in fig. 3-15) and conversely the 
opposit effect upon transient knockdown of miR-182 (Fig. 3-15) 
Consistent with the results obtained for the two other cell lines, no significant 
differences in migration and invasion was observed upon overexpression or 
knockdown of miR-183 or miR-96 in D458Med.  
As a result of all in vitro migration experiments, we further focused on the role 





Figure	   3-­‐15.	   Boyden	   chamber	  assays	   showed	  miR-­‐182	  expression	   to	  be	  significantly	  associated	  with	  the	  migratory	  phenotype	  of	  D458Med	  cells.	  	  	  	  
Results	  	  
	   71	  
3.3.4	  Microchannel	  assay	  
Microchannel experiments were carried out in close collaboration with our 
collaborators Dr. Ralf Kemkemer and Claudio Rolli from the Max Planck Institute 
for Intelligent Systems, Stuttgart, Germany. This micro-fabricated device with 
channel structures mimicking a 3-dimensional in vivo environment was first 
described by Rolli et al. (Rolli 2008; Rolli et al. 2010). This method enabled us to 
monitor cell migration through accurately defined structures in real-time.  
The interaction between cells and the channels were categorized into three 
activities: penetration, invasion, and permeation (Rolli et al. 2010). The 
invasiveness of tested cell is defined as the percentage of invasive activity 
(invasion and permeation) in all activities observed. Time-lapse pictures in     
Fig. 3-16 were captured from video S1, showing an example of a DAOY cell 
permeating a 5 µm wide channel (The three different cell behaviors are 
demonstrated in video S1~S4).  	  
	  




For microchannel experiment, the specially designed microchannel chip 
contains 4 different sized channels thus we can observe cell behaviors in them 
in parallel within one experiment. According to previous experiences from the 
collaborator, maintenance of the channel structure of the smallest channel, 
3x11x100 µm, is very difficult. Besides, cells usually cannot get into the channel 
of this small size. As a result, we focused on the three bigger channels with       
5 µm, 7 µm, and 10 µm width respectively. 
We chose to investigate DOAY cells, which had shown the strongest 
phenotypic differences in established migration assays. In the first experiment, 
we compared DAOY cells with empty vector, one miR-182 overexpresing clone, 
transient knockdown of miR-182 and untreated mock control. We observed a 
gradually decreased invasiveness from the widest channels to the smalles ones. 
However, 7x11x300 µm and 10x11x100 µm channels showed similar 
invasiveness between miR-182 overexpression and empty vector control or 
miR-182 knockdown against mock control. In contrast to this, strong differences 
in migration propensity were observed in the smallest sized channels (5x11x300 
µm) upon overexpression and knockdown of miR-182, respectively. (Fig. 3-17) 
	  
Figure	  3-­‐17.	  The	  first	  experiment	  with	  microchannels	  showed	  that	  5	  μm	  wide	  channels	  are	  the	  most	  selective	  condition	  to	  detect	  differences	  in	  the	  invasiveness	  of	  DAOY.	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After this encouraging finding, we carried out two more replication 
experiments testing all different conditions of DAOY cells in 5 µm micro-
channels. In three individually processed tests, stable overexpression of miRNA-
182 increased the average invasiveness to 2.6-fold (182K1) and 2.9-fold 
(182K2) compared to empty vector transfected DAOY cells (pCMX). Inversely, 
DAOY with transient KD of miR-182 showed a significantly reduced 
invasiveness of 0.6-fold against the negative control. (Fig. 3-17; Video S1-S4) 
Another adhesive medulloblastoma cell line, Med8A, was also subjected to 
microchannel assays. Consistent with our findings in DAOY, as well as in the 
scratch assay, Med8A cells transfected with empty vector (pCMX) showed 
virtually no migration and were not capable of invading the 5µm channels. After 
miR-182 overexpression, Med8A cells became moderately invasive, and a 
considerable proportion of cells were able to invade the microchannels (Fig. 3-
18; Video S5/S6)  
	  




3.4	   Overexpressing	  miR-­‐182	  in	  vivo	  
To further assess the pro-migratory properties of miR-182 in vivo, we 
performed orthotopic xenograft experiments with our colleborator Prof. Dr. Olaf 
Witt and Dr. Till Milde from the Division of Clinical Cooperation Unit Pediatric 
Oncology, DKFZ. DAOY cells with empty vector transfected were compared 
versus overexpression of miR-182. MRI revealed tumor formation at 4.6 months 
(mean, range: 3-7) after implantation. Once a tumor was discovered, mice were 
sacrificed and the xenogragt was taken out for analysis. Haematoxylin & eosin 
staining of xenograft sections demonstrated tumor formation by all clones 
irrespective of the transfected construct. The pathologist found that DAOY-
182K1 and DAOY-182K2 had extensively infiltrated into the surrounding normal 
cerebellum tissues, giving rise to countless small colonies widely distributed 
throughout the brain (green arrowheads in Fig.3-18 a, b, d, e), whereas the 
control clone DAOY-pCMX formed tumors with a clear boundary (Fig.3-18 c, f). 
Notably, both xenografts derived from DAOY-182K1, and DAOY-182K2 showed 
a morphology with larger cells, reminiscent of large cell / anaplastic (LC/A) type 
medulloblastoma (Fig.3-18 g, h, i). Furthermore, miR-182 overexpressing 
tumors frequently demonstrated leptomeningeal dissemination (Fig.3-18 j - o). 
Overexpression of miR-182 did not affect the latency of the xenograft formation, 
which was in line with our in vitro results on cell proliferation. 	  	  	  	  
Figure	   3-­‐18.	   (on	   the	  next	  page)	  Haematoxylin	  &	  eosin	  staining	  of	  DAOY	  xenograft	   sections.	   (a),	   (b)	  Both	  DAOY-­‐182K1	  and	  DAOY-­‐182K2	   invaded	  into	   adjacent	   normal	   cerebellum,	   forming	   small	   colonies,	   indicated	   by	  green	   arrows.	   (c)	   DAOY-­‐pCMX	   formed	   a	   xenograft	   in	   solid	   tumor	   with	  clear	  boundary,	  indicated	  by	  yellow	  arrows.	  (d),	  (e)	  Magnified	  view	  of	  the	  Infiltrating	   colonies	   of	   DOAY-­‐182K1	   and	   DAOY-­‐182K3	   into	   the	   normal	  cerebellum.	   (f)	   Magnified	   view	   of	   the	   boundary	   between	   normal	  cerebellum	  and	  DAOY-­‐pCMX	  xenograft.	  (g),	  (h),	  (i)	  Both	  DAOY-­‐182-­‐K1	  and	  DAOY-­‐182K2	   showed	   larger	   cellular	   size	   than	   DAOY-­‐pCMX,	  morphologically	   resembling	   LC/A	   medulloblastoma,	   which	   is	   associated	  with	  a	  highly	  malignant	  and	  invasive	  clinical	  phenotype. (j)	  –	  (o)	  A	  higher	  incidence	   of	   leptomeningeal	   spread	   was	   seen	   in	   tumors	   overexpressing	  miR182	  compared	  to	  controls	  (black	  boxes:	  position	  of	  the	  400x	  image	  in	  the	  100x	  image).	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3.5	   Video	  clip	  legends.	  
Video	  1	  (Video1_DAOY-­‐182K2.avi)	  DAOY	   cells	   stably	   transfected	   with	   miR-­‐182	   were	   seeded	   closely	   to	   the	  channels.	  A	   representative	  permeation	  activity	   is	   shown	   in	   the	   third	  channel	  on	  the	  right	  hand	  side.	  Duration	  24	  h;	  scale	  bar,	  100	  μm.	  	  
Video	  2	  (Video2_DAOY-­‐pCMX.avi)	  DAOY	  cells	  stably	  transfected	  with	  empty	  vector	  (pCMX).	  All	  four	  channels	  on	  the	   right	   hand	   side	   showed	   the	   typical	   penetrative	   behavior.	   Cells	  continuously	  tried	  to	  enter	  the	  channels	  throughout	  the	  experimental	  period,	  while	   nuclei	   were	   not	   able	   to	   enter	   the	   channels.	   Duration	   24	   h;	   scale	   bar,	  	  	  	  100	  μm.	  	  
Video	  3	  (Video3_DAOY-­‐si182.avi)	  DAOY	   cells	   with	   miR-­‐182	   knockdown	   after	   24h.	   Less	   invasive	   activity	   was	  observed	  and	  the	  cells	  were	  only	  trying	  to	  enter	  the	  channels	  for	  short	  periods	  of	  time.	  Duration	  24	  h;	  scale	  bar,	  100	  μm.	  	  
Video	  4	  (Video4_DAOY-­‐siCtrl.avi)	  DAOY	   cells	   with	   scrambled	   siRNA	   treatment.	   A	   DAOY	   cell	   invaded	   into	   the	  channel	  and	  migrated	  until	  the	  middle	  of	  the	  channel.	  Then	  the	  cell	  returned	  to	  the	   starting	   point.	   This	   special	   invasion	   behavior	   could	   be	   observed	   in	   the	  second	  channel	  on	  the	  right	  hand	  side.	  Duration	  24	  h;	  scale	  bar,	  100	  μm.	  	  
Video	  5	  (Video5_Med8A-­‐182K2.avi)	  Med8A	  cells	  stably	  transfected	  with	  miR-­‐182.	  Most	  of	  the	  cells	  remained	  in	  the	  same	  position,	  and	  generally	  did	  not	  enter	  the	  channel.	  The	  fourth	  channel	  on	  the	  left	  hand	  side	  showed	  a	  example	  for	  a	  single	  invasion.	  Duration	  24	  h;	  scale	  bar,	  100	  μm.	  	  
Video	  6	  (Video6_Med8A-­‐pCMX.avi)	  Med8A	  cells	  stably	  transfected	  with	  empty	  vector.	  All	  cells	  included	  in	  the	  field	  of	  view	  remained	  in	  a	  similar	  position.	  No	  invasive	  behaviors	  were	  observed	  at	  all.	  Duration	  23:20	  h;	  scale	  bar,	  100	  μm..	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4	   DISCUSSION	  
The present study provided clear evidence for subgroup-specific miRNA 
expression profiles in medulloblastoma. In line with the association of high miR-
182 expression with metastatic disease in patients, miR-182 was shown to play 
an important role in medulloblastoma cell migration in vitro and in vivo. These 
findings collectively might help to develop novel targeted treatment options for 
disseminated medulloblastoma. 
4.1	   Non-­‐SHH	  medulloblastoma	  display	  a	  distinct	  
microRNA	  expression	  pattern	  
Several recent studies have demonstrated that medulloblastoma is not a 
single disease, but consists of biologically distinct subgroups (Kool et al. 2008; 
Cho et al. 2010; Northcott et al. 2010; Remke et al. 2011) and is likely derived 
from different cells of origin (Gibson et al. 2010; Sutter et al. 2010). In this study, 
111 medulloblastoma samples with detailed clinico-pathological information 
were investigated for characteristic miRNA expression patterns. Both by 
unsupervised hierarchical clustering (HCL) (Fig.3-1) and Principal component 
analysis (PCA) analysis (Fig.3-2), SHH-driven mebulloblastomas showed the 
clearest separation from other medulloblastoma subtypes based on genome-
wide miRNA expression patterns.  
 Whereas previous transcriptome-based studies identified four major 
subgroups of medulloblastoma (Northcott et al. 2010; Remke et al. 2011), 
miRNA expression profiles in the present study revealed three major clusters by 
unsupervised HCL or PCA. This might be owing to the small sample size and 
especially under-representation of group C medulloblastoma samples in our 
screening cohort (9% in screening cohort; 26% in Northcott et al. study). 
Besides, our screening data set contains of a larger proportion of adult patients 
than the Northcott et al. study (34.4% vs. 13%), thus the subgrouping would fit to 
the recently published study indicating that adult medulloblastoma mainly 
consist of three major subgroups, SHH, WNT and group D (Remke et al. 2011). 
A larger and more representative cohort of childhood medulloblastomas may 




4.2	   Novel	  miRNA	  candidates	  found	  aberrantly	  
upregulated	  in	  Non-­‐SHH	  medulloblastoma	  	  
A robust 26-miRNA signature identified by SAM analysis was readily able to 
separate SHH medulloblastomas from non-SHH medulloblastomas (Fig.3-3). 
The reliability of this signature was confirmed in an independent validation data 
set with a larger sample size obtained on a different microRNA microarray 
platform. 
Pang et al. summarized frequently deregulated miRNAs in medulloblastoma 
from three earlier major studies, which all focused on a very prominent onco-
miR cluster, namely the miR-17/92 cluster, which is frequently activated in SHH 
medulloblastoma, as well as on the single miRNAs miR-128-1/2, miR-19a, miR-
106b, and miR-191 (Northcott et al. 2009; Pang et al. 2009). However, our study 
was the first to identify a miRNA cluster that might be functionally involved in the 
dissemination of non-SHH medulloblastomas based on the association with 
metastatic disease in primary medulloblastoma samples. 
The miRNA signature in this study was comprised of many novel miRNA 
candidates, which have not been previously implicated in medulloblastoma or 
other cancer types, such as miR-455 (hsa-miR-455), miR-182 (hsa-miR-182), 
miR-183 (hsa-miR-183), and miR-96 (hsa-mir-96), which were all found to be 
overabundant in non-SHH medulloblastoma (Table 3A).  
Three candidate miRNAs (miR-182, miR-183, and miR-96) were chosen from 
the four most differentially regulated miRNA candidates in the miRNA signature 
based on the fact that they comprise a common miRNA cluster on chromosome 
7q. Under physiological conditions, these miRNAs show a highly specific 
expression pattern restricted to human and murine sensory organs (Xu et al. 
2007). It was previously established that they play an important role in retinal 
development and stem-cell maintenance in mice (Loscher et al. 2007; Loscher 
et al. 2008; Viswanathan et al. 2009).  
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4.3	   Mir-­‐183	  miRNA	  cluster	  is	  significantly	  associated	  with	  
metastatic	  stage	  of	  medulloblastoma	  
In the present study, the expression patterns of candidate miRNAs were 
confirmed with QRT-PCR in both the screening cohort and a non-overlapping 
validation cohort. Non-SHH medulloblastoma showed a higher expression of all 
three retinal miRNAs, whereas the expression in SHH medulloblastomas was 
similar as the expression detected in a pooled normal cerebellum RNA sample. 
An earlier study demonstrated miR-182 and miR-183 were overexpressed in 
WNT subgroup medulloblastoma (Gokhale et al. 2010). This study, however, 
clearly showed that aberrant expression of the three retina-specific miRNAs is 
not limited to this subgroup. This finding was independently confirmed in a third 
dataset recently published by Cho et al. (Cho et al. 2010).  
Abundance of all members of the miR-183~96~182 cluster was shown to be 
significantly higher in medulloblastomas located in the cerebellar midline, 
whereas miR-182 and miR-96 also showed a significantly higher expression in 
metastatic medulloblastoma. Notably, the significant association with tumor 
location is in line with previously reports showing that SHH medulloblastoma is 
frequently found in the cerebellar hemispheres rather than in the cerebellar 
midline (Polkinghorn et al. 2007) and is associated with a lower incidence of 
metastatic dissemination (Northcott et al. 2009). Metastatic stage at diagnosis is 
an important clinical factor to predict patient outcome in medulloblastoma. 
However, the expression of retina-specific miRNAs was not significantly 
associated either with overall or progression-free survival in our dataset. This 
might be explained by the fact, that WNT subgroup medulloblastomas, which 
have the best outcome of all medulloblastoma subtypes (Northcott et al. 2009; 
Pfister et al. 2009), were also contained in the “non-SHH” cluster derived from 




4.4	   Mir-­‐183	  and	  miR-­‐96	  have	  milder	  effect	  on	  the	  
metastatic	  phenotype	  of	  medulloblastoma	  cells	  in	  vitro	  
The first miR-183~96~182 cluster member along the transcription direction 
within the orthologous region chromosome 7q32.2 is miR-183. It was reported to 
act as an oncomir and to promote tumor cell migration via downregulation the 
tumor suppressor genes EGR1 and PTEN (Sarver et al. 2009). The authors 
found that miR-183 is overexpressed in multiple cancer cell lines including 
synovial sarcoma, rhabdomyosarcoma (RMS), and colon cancer. Indeed, they 
showed that the transcription factor EGR1, which is downregulated in subsets of 
these tumors, is a downstream target of miR-183,. Applying anti-miR-183 
treatment, expression of EGR1 was rescued, and another tumor suppressor 
gene, PTEN, was also reactivated. Functionally, anti-miR-183 treatment could 
block the migration phenotype of these cells (Sarver et al. 2010). 
Conversely, other studies reported overexpression of miR-183 to inhibit the 
migratory phenotype of lung and breast cancer cells (Wang et al. 2008; Lowery 
et al. 2010). As a common finding, both studies showed that miR-183 is a 
potential metastasis inhibitor via regulation of VIL2 and Ezrin, key components 
of metastatic dissemination (Hunter 2004). 
Similar contradictory findings have also been reported for miR-96. Yu et al. 
demonstrated that miR-96 acts as a tumor suppressor gene in pancreatic cancer 
through silencing of the KRAS oncogene. In addition, overexpression of miR-96 
inhibited proliferation, migration, and invasion of pancreatic cancer cells in vitro 
and also affected tumor cell growth in vivo (Yu et al. 2010). 
Shortly thereafter, another group showed that miR-96 was working as an 
onco-miR in breast cancer by silencing the tumor suppressor gene FOXO3a. 
and its downstream targets p21 and p27, both well-known cyclin D1 inhibitors. 
This would ultimately result in the induction of proliferation of breast cancer cells 
in the proposed model (Lin et al. 2010).  
In the present study, the overexpression of miR-183 and miR-96, did not 
significantly elevate the migratory ability of DAOY and D458Med cell lines. This 
was at first surprising, because these three miRNAs candidates were reported to 
be transcripted in a single polycistronic transcript (Xu et al. 2007). Furthermore, 
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the same study demonstrated that two members could synergize to reach a 
better inhibition of predicted target genes. However, it might still be the case, 
that each member of the cluster has a distinct biological role in fine-tuning the 
expression levels of different sets of target genes post-transcriptionally and 







4.5	   MiR-­‐182	  has	  the	  strongest	  impact	  on	  the	  migration	  
phenotype	  of	  medulloblastoma	  cells	  in	  vitro	  and	  in	  vivo	  
MicroRNA miR-182 has also been implicated in the inhibition of proliferation 
and invasion of human lung cancer cells in a recent study (Zhang et al. 2011). 
The authors further identified the cortactin gene (CTTN) as a miR-182 target. 
Overexpression of miR-182 decreased the expression levels of CTTN in lung 
cancer cells thereby suppressing proliferation and invasion in vitro and in vivo. 
The CTTN gene is frequently upregulated in breast cancer and associated with 
decreased survival owing to the high incidence of lymph node and distal 
metastases. Taken together with previous results from Wang et al., miR-182 and 
miR-183 might co-operate as tumor suppressor genes in lung cancer 
Contradicting these findings in a different cellular context, there is also strong 
evidence now showing the role of miR-182 a tumor promoter in breast cancer. 
Maskwa et al. provided solid evidence that one of the frequently deregulated 
genes in breast cancer, BRCA1, is silenced in sporadic breast cancer by 
hyperactivation of miR-182 (Moskwa P 2011). The tumor promoting role of miR-
182 was further substantiated in melanoma cells, where it exerts at least a part 
of its effect via suppression of FOXO3 (forkhead box O3) (Segura et al. 2009). 
Furthermore, a later study successfully rescued the dissemination of melanoma 
cells in mice by applying an anti-miR-182 treatment (Huynh et al. 2011). 
Three different in vitro migration assays were used in this study. Both the 
classic (scratch assay and Boyden chamber assay) and a novel methodology 
(3D microchannel assay) showed concurrent findings. MiR-182 showed the 
most obvious impact on the scratched wound healing speed and the ability to 
migrate through a small pored membrane in the Boyden chamber assay across 
all three medulloblastoma cell lines tested. Consistent with this, opposite results 
were observed after anti-miR siRNA treatment. Although DAOY and D458Med 
have relatively high endogenous miR-182 expression levels, elevation of miR-
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Conversely, the knockdown of miR-182 in Med8A cells, which have a very 
low miR-182 baseline expression, had no influence on the migration ability of 
these cells. For the overexpression study of miR-182 in Med8A only one of two 
stably overexpressing clones showed a clearly increased migration, whereas the 
second clone only showed a trend. This might be explained by of the fact that 
Med8A cells with their low baseline miR-182 expressionmight be less dependent 
on miR-182 than medulloblastoma cells with a high baseline expression of this 
miRNA. 
Nevertheless, DAOY with miR-182 stably overexpressed also showed a very 
strong migratory and invasion phenotype in vivo, which also lead to a more 
pronounced leptomeningeal spread of the xenograft in vivo, thus frimly 
confirming the important role of miR-182 in the metastatic dissemination of non-
SHH medulloblastoma.  
Further strengthening this distinct function of miR-182, our collaborators from 
Boston recently found an increased migration propensity in another 
medulloblastoma cell line, UW426, and confirmed our findings in DAOY. Cho et 
al. corroborated that miR-182 has the strongest effect on the migration 
phenotype and the mildest effect on apotosis and cell viability (data co-




In conclusion, our study shows the first convincing evidence that 
overexpression of miR-182 elevates the pro-migratory phenotype of 
medulloblastoma cells in vitro and in vivo. Thereby we provide strong indication, 
that overexpression of miR-182 in non-SHH medulloblastoma contributes to 
leptomeningeal metastatic dissemination. Thus, targeted inhibition of miR-182 
could serve as a molecular therapeutic strategy for the treatment of patients with 
metastatic medulloblastoma as pre-clinically demonstrated for melanoma. 
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6	   APPENDIX	  
6.1	   RNA	  quality	  analysis	  with	  RNA	  integrity	  number	  (RIN)	  
	  
“The	   RNA	   integrity	   number	   (RIN)	   is	   a	   software	   tool	   designed	   to	   help	  
scientists	   estimate	   the	   integrity	   of	   total	  RNA	   samples.	   The	   expert	   software	  
automatically	   assigns	   an	   integrity	   number	   to	   an	   eukaryote	   total	   RNA	  
sample.	  Using	  this	  tool,	  sample	  integrity	  is	  no	  longer	  determined	  by	  the	  ratio	  
of	   the	   ribosomal	   bands,	   but	   by	   the	   entire	   electrophoretic	   trace	   of	   the	  RNA	  
sample.	   This	   includes	   the	   presence	   or	   absence	   of	   degradation	   products.	   In	  
this	  way,	  interpretation	  of	  an	  electropherogram	  is	  facilitated,	  comparison	  of	  
samples	  is	  enabled	  and	  repeatability	  of	  experiments	  is	  ensured.	  The	  assigned	  
RIN	   is	   independent	   of	   sample	   concentration,	   instrument	   and	   analyst	  
therefore	   becoming	   a	   de	   facto	   standard	   for	   RNA	   integrity.”	   The	   RNA	  Integrity	   Database	   (RINdb)	   (http://www.chem.agilent.com/rin/	  _rinsearch.aspx)	  showed	  that	  the	  average	  RIN	  for	  frozen	  brain	  tissue	  (both	  normal	   and	   tumor,	   yet	   no	   medulloblastoma)	   is	   around	   8.1	   ~	   9.7.	   As	   a	  result	  we	  set	  the	  RIN	  cut-­‐off	  at	  8.0.	  Information	  from	  Agilent	  official	  web-­‐site	  (http://www.home.agilent.com/)	  	  
	  	  
